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ABSTRACT
A novel high flow rate cell capture design was introduced to overcome the
limitations of the current technologies or methods for rare target cell capture. Even
though the rare target cell capture using BioMEMS technology has great potential for
cancer diagnosis, previous rare cell capture research could not overcome the
limitations of low flow rate or low recovery rate.
Rare cell research requires precise sample preparation for accurate results. A new
method of preparation for a single or a precise number of target cell was introduced.
Current sample preparation methods which are not suitable for rare cell research, such
as CTC capture or single cell analysis do not provide precise cell counts below 100. A
cell collection chip was designed and used with a polyimide removed capillary tube
to collect an exact number of target cells under a microscope.
To optimize the dimensions of the high flow rate design, CFD (Fluent v6.3,
ANSYS, Inc., Canonsburg, PA, USA) simulation was used. The design focused on a
high flow rate at inlet and low axial and lateral velocities in the cell capture regions
with a small footprint. Based on the simulation results, the dimensions for several
prototypes were determined and fabricated in PMMA.
The CTCs, MCF-7 cells, were captured flow rates up to 750 µL/min from 40%
red blood cells with 80% recovery rate using the high flow rate device.
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CHAPTER 1: INTRODUCTION

1.1 Human Breast Cancer
Human breast cancer is the leading cause of death from cancer for women in this century
[1, 2]. More than 211,000 American women are told that they have this disease every year.
Estimated new cases and deaths from breast cancer in the United States in 2010 were
209,060 cases (207,090 for female and 1,970 for male) and 40,230 deaths (39,840 for female
and 390 for male) [3]. Because of the continuing efforts to develop screening and diagnosis
technology and the improvements in surgical and other treatment methods, survivors`
lifetimes have increased and the mortality, the rate of deaths compared to the number of
cases, decreased over the last few decades [3, 4]. However, breast cancer is still one of the
most dangerous diseases leading to death and it is very hard to treat once it has metastasized
to other organs in the patient`s body [2, 3, 5]. Figure 1.1 shows the incidence and mortality
rates of breast cancer in the USA.
1.1.1

Origins and Characteristics of Cancer in the Human Body

Normal cell growth occurs at times, to replace worn cells, to grow tissue during
development, or to create new life during pregnancy. It is normally very well controlled.
However, cells can sometimes grow improperly and multiple mutations can make normal
cells into tumor cells [6-8]. Cancer cells are uncontrolled, malignant, immortal, and do not
stop growing as long as sufficient nutrients are available from their environment. They may
travel anywhere in the body via a single cell migration [9-11]. The origin of cancer is not yet
clearly defined, but some basic causes of cancer are chemicals, radiation,
1

Figure 1.1 Incidence and mortality of breast cancer in United States [12]
and viruses [13]. Tumors can be localized or metastasize to other organs. The invasion of
tumor cells can start at the very beginning of tumor development [11, 14]. Moreover, the
mechanism of metastasis is not well understood [10, 11].
1.1.2

Staging of Human Breast Cancer and Survival Rates

The stage at which breast cancer is detected significantly affects the survival rates [15].
The time course of breast cancer is divided into four stages. Alternatively, it can be
subdivided as six stages based on the size, number of palpable lymph nodes, and metastasis
2

of the tumor [4, 16, 17]. A schematic diagram shown in Figure 1.2 indicates the locations of
the axillaries and nodes.
Stage 0 is the condition of no primary tumor or carcinoma in situ. Stage 1 is early stage
invasive breast cancer and the tumors are less than 2 cm in dimension and located only in the
breast. Ten year relative survival rates for Stage 0 are 95% and for Stage 1 are 88%. Stage 2
is subdivided into two sub-categories (Stage 2-A and Stage 2-B) based on tumor size and
lymph node involvement. Stage 2-A has two cases. Either the size of the tumor is between 2
cm and 5 cm and has not spread to the surrounding lymph nodes or the size of tumor is less
than 2 cm but has spread to up to three axillary underarm lymph nodes. Stage 2-B also
includes two cases. Either the size of the tumor is larger than 5 cm without spreading to the
surrounding lymph nodes or the size of tumor is between 2 and 5 cm with spreading to up to
three axillary underarm lymph nodes.

1. Low axillary, Level 1
2. Mid-axillary, Level 2
3. High axillary, apical, Level 3
4. Supraclavicular
5. Internal mammary nodes

Figure 1.2 Schematic diagram of the breast and regional lymph nodes [17]
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Stage 3 is subdivided into two categories (Stage 3-A and Stage 3-B) based on the tumor
size and lymph node involvement. If the size of tumor is less than 5 cm in diameter and
spreads to four to nine underarm lymph nodes, it is stage 3-A. A tumor over 5 cm size
involved with up to nine axillary nodes or to internal mammary nodes, it can be also stage 3A. Stage 3-B is reached when the tumor spreads through the chest wall or skin, to the ribs
and muscles. During the last stage, Stage 4, the tumor spreads to other organs in the body
such as the bones, lungs, liver, and brain. Ten year relative survival rates for Stage 2 are 66%,
for Stage 3 36%, and for Stage 4 just 7% [15].
1.1.3

Human Breast Cancer Treatment at Different Stages

The method of treatment of breast cancer can be guided by the stage of the breast cancer.
The stage of breast cancer reflects the eventual mortality and is also directly related to the
quality of life for the patient, because earlier detection requires easier, less invasive treatment.
Figure 1.3 shows the relationship between survival rate and the stage of breast cancer [15].
For early stages, such as Stages 1 or 2, breast-sparing surgery, also called breastconserving surgery, and radiation therapy are commonly used as the primary treatment.
Breast-sparing surgery is the removal of the breast cancer tissue, or the removal of a lump or
part of the breast, but not the breast itself. At Stage 3, local treatment, including surgery and
radiation therapy, and systemic treatment, comprised of chemotherapy or hormonal therapy,
are needed to remove the cancer and to prevent additional spreading. Stage 4 breast cancer is
commonly treated by chemotherapy and hormonal therapy with surgery followed by
radiation, including other metastasized body parts. Therefore, early detection will allow the
easier treatment, potentially a longer life time, and a better quality of life [5, 18].
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Figure 1.3 Relative survival rates of breast cancer patients combined cancer stage group from
1985 to 1990 [15]

1.2 Diagnosis of Human Breast Cancer
1.2.1

Historical Review of Breast Cancer Detection

In the early 20th century, X-ray imaging was suggested for detection of breast cancer as
an initial breast cancer diagnosis. However, mammography did not begin to emerge as a
clinical tool until the 1960s. Later, advances in technology led to the use of other
technologies, such as ultrasound (US), magnetic resonance imaging (MRI), and optical
imaging, as acceptable and recommendable diagnostic methods. Major improvements in the
past 30 years include the reduction of radiation doses, automatic control of exposure,
development of better imaging technology, digitizing of images, and computer-aided
detection [4, 19].

5

Figure 1.4 A history of breast cancer screening [4].
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1.2.2

Current Clinical Methods

Currently, screening and diagnosis of breast cancer can be done using various
technologies such as Full Field Digital Mammography (FFDM), Computer-Aided Detection
and Diagnosis (CAD), Ultrasound (US), Magnetic Resonance Imaging (MRI). Figure 1.5 is a
picture of a commercial mammography machine for breast cancer detection. Routine
screening using these techniques decreased the mortality of breast cancer to 25 ~ 30 percent
among women 50 to 70 years old age [4]. However, the sensitivity of current breast cancer
screening methods is not high enough. Clinical breast examination, mammography, and MRI
detect 17.8%, 40%, and 71.7% of all breast cancers, respectively. For invasive breast cancer,
the sensitivity of clinical breast examination is down to 17.9%, 33.3%, and 79.5% for
mammography, and MRI, respectively [20]. The combination of these technologies with a

Figure 1.5 Commercial mammography machine for breast cancer detection
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biopsy is recommended to make up for the weak points in each technique, but is not perfect
and does not address the need for early stage detection; Ultrasound can detect 40% of breast
cancer and the combination of mammography and ultrasound can detect 49% [21].
Commercial technology can detect tumors with diameters of approximately 1 cm usually [18,
22]. Mammography, ultrasound, and MRI can detect invasive tumors with mean sizes of 13.2
mm, 15.1 mm, and 12.4 mm, respectively [21]. The resolution or detectable minimum size
tumor also depends on the density of the breast, the location of the tumor, and other
conditions. Due to the limitations of these commercial systems and methods, it is necessary
to develop or find other ways to accomplish early detection and diagnosis.
1.2.3

BioMEMS for Diagnosis

Micro Electro Mechanical System (MEMS) technology was developed as a new research
field from microelectronics fabrication in the 1960`s and commercialization began in the
1980`s. The applications of MEMS are varied and it has a great potential [23]. MEMS are
commonly used as sensors, analyzers, or actuators in mechanical, electrical, optical, chemical,
biological, and medical applications.
As a subset of MEMS, BioMEMS has specialized in the role of sensor, analyzer, and
actuator for micro total analysis systems for biological, clinical, and biomedical applications
[24-29]. One of the most promising BioMEMS uses is the field of diagnostics. In diagnostics,
BioMEMS give a better option compared to commercial technology or products because of
the small sample requirement, fast response time, low cost, disposability, and small footprint.
Based on the these advantages, commercial products using BioMEMS technology are in the
market including a portable blood tester, CTC detection, and capsule endoscopy (See the
Figure 1.6.)
8
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(a)
(b)
(c)
Figure 1.6 Commercial diagnosis products of BioMEMS technology: (a) portable blood
tester [30], (b) CellSearch System [31], and (c) capsule endoscopy [32]
Moreover, BioMEMS technology may be a solution to reach the requirement of the early
stage human breast cancer diagnosis. Many researchers have demonstrated methods for early
human breast cancer detection or separation [33-44]. Veridex, LLC launched a CellSearch
system (Veridex, Raritan, NJ, USA) for circulating tumor detection. However, it has not
reached the standard of performance necessary for point-of-care uses for human cancer
diagnosis at an early stage.

1.3 Motivation for This Project
1.3.1

BioMEMS Approach for Breast Cancer Diagnosis

BioMEMS approaches have been introduced for tumor detection [34-37, 39-46]. One of
the approaches for the early stage breast cancer diagnosis is the separation or capture of
circulating tumor cells (CTCs) because it has great potential for easy routine screening and
can potentially produce a diagnosis at an early stage. CTCs are present on the earliest stages
of tumor development [11, 14]. Moreover, captured or separated CTCs may minimize the
bio-noise or uncertainty of identification. Captured CTCs can be clearly confirmed or
identified with a type of tumor, either a benign or malignant tumor or an epithelial non-tumor,
9

by other subsequent analysis, such as PCR or LDR. So, it can be a direct test instead of
mammography and biopsy.
The methods of target cell detection and separation using BioMEMS can be classified as
gene analysis-based [47-50], optically-based [27, 51-53], size-based [29, 33, 42, 44, 45, 5458], or affinity-based [34-36, 43, 59, 60]. Even though BioMEMS have a great potential for
diagnostics, human breast cancer diagnosis as a point-of-care application has not been
realized due to the poor sensitivity, low detection rate, or low throughput. These limitations
actually are due to the rarity of tumor cells in the blood particularly at the early stages. Most
recently published accomplishments are from Nagrath, et al. 2007 [34], Stott, et al. 2010 [43],
Wang, et al. 2011 [40], Feng, et al. 2003 [36], and Adams, et al. 2008 [35]. Nagrath showed
the successful CTC capture from human whole blood using BioMEMS. However, the flow
rate was too low, 1mL/hr to get a high recovery rate, and the recovery rate was less than 80%.
Stott reported a 79% recovery rate with a flow rate of 1.2 mL/hr [43]. Wang achieved a 95%
recovery rate but at 2 mL/hr. Adams obtained better results, a flow rate of 1.92 mL/hr to get a
maximum recovery rate (97%), with multiple parallel sinusoidal channels using spiked rabbit
blood. However, it would take 4 hours to evaluate a 7.5 mL sample; the required minimum
sample volume of 7.5 mL is necessary to get acceptable accuracy and to define the survival
rate [61]. Moreover, the initial number of target cells in sample preparations for most of these
experiments could not be clearly verified because they were controlled and counted
statistically. This uncertainty in sample preparation affects the evaluation of the results.
Therefore, the technology is not fast enough and not yet suitable for clinical use.
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1.4 Goals of This Research
A method of diagnosing human breast cancer at an early stage by taking advantage of
BioMEMS technology could overcome the limitations of current commercial methods. This
project can save more lives with an easy and economical method since BioMEMS
technology has the potential to replace expensive and time consuming commercial breast
cancer diagnostic methods. This new technology can economically replace the current
methods of breast cancer diagnosis.
This research was focused on a new method to introduce a connection between
BioMEMS technology and the clinic for diagnosis with a point-of-care concept. It will
demonstrate a suitable design, method, and experimental confirmation to be used in a
medical or clinical uses with fast results and high capture accuracy from precisely prepared
target cell populations in large sample volumes using BioMEMS. Moreover, the target cells
are not only breast cancer cells, but also any kind of circulating tumor cells with proper
biomarkers such as colorectal cancer, breast cancer, lung cancer, ovarian cancer, or prostate
cancer [62]. Therefore, the application of this method can be much broader and the impact
can be high. By developing, polymer micro devices manufacturing cost can be minimized
and a disposable diagnosis system realized. The point-of-care device can maximize access to
cancer diagnosis. Easy and simple accessibility of cancer diagnosis (as a manner of time, cost,
and location or portability) should eventually reduce the mortality of cancer.
The goal of this research was the development of a disposable polymer micro CTC
capture device with a high flow rate, a high recovery rate, and a high purity without pretreatment of the sample. Moreover, the device should allow further molecular analysis to
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minimize false-positive results and to obtain more specific and detailed information after
target cell capture.
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CHAPTER 2: BACKGROUND

2.1 Introduction
A basic background on human blood including physical/biological properties, immune
systems, and blood rheology are given in this chapter since circulating tumors cells (CTCs)
exist in the human peripheral blood. Biological or physical properties of blood cells can
distinguish and identify the CTCs from blood cells. The immune system uses fundamental
antigen/antibody reactions, which can be used for specific CTC capture. Blood rheology is
very important for CTC capture or separation because it changes the blood properties, and
affects the lateral location of CTCs in devices. Moreover, non-Newtonian blood flow is an
important factor for microfluidic systems.
Current technologies for CTC capture are summarized in this chapter. Six approaches
have been used and the advantages and disadvantages of each are discussed. Commercial
products are also reviewed. Based on the technology review, the goals of this research are
explained.

2.2 Peripheral Human Blood
2.2.1

Physical Properties

Blood is a viscous fluid mixture of 55 % plasma and 45 % cells. The components of
plasma are 92 % water and 8 % protein, metabolites and ions [1, 2]. The cells in blood can be
divided into red blood cells (Erythrocytes), white blood cells (Leukocytes), and platelets
(fragments of megakaryocytes). The density of the plasma and the cells is about 1,025 kg/m3
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and 1,125 kg/m3 respectively. Red blood cells or erythrocytes comprise 95% of whole blood
cells, 4 ~ 6

106 cells/µL. Red blood cells have a biconcave disk shape because the nucleus

is squeezed out and ingested by the macrophage during creation in bone marrow.
Erythrocytes can provide the optimal deformability with maximum surface area for gas
exchange. The platelets compose around 4.9% of whole blood, 1.5 ~ 4

105 cells/µL. The

white blood cells or leukocytes count as 0.1% of cellular components of blood, 4 ~ 11

103

cells/µL (normally 1/700 number of red blood cells). The size and shapes of blood cells are 6
~ 8 µm diameter with 1 ~ 3 µm thickness for normal red blood cells, 7 ~ 20 µm diameter
with spherical shape white blood cells, and 2 ~ 5 µm platelets. Table 2.1 shows the size and
shape of the different blood cells.
Leukocytes can be separated into five different types in two groups based on the specific
granularity or nucleus type [3]. The five different types of leukocytes are neutrophils,
eosinophils, basophile, lymphocytes, and monocytes.

Neutrophils, eosinophils, and

basophils are called granulocytes, granular leukocytes, or polymorphonuclear leukocytes due
to the presence of granules in their cytoplasm. Lymphocytes, monocytes, macrophages, and
dendritic cells are grouped as agranulocytes (agranular leukocyte) or mononuclear leukocytes.
The proportion of each type of leukocyte are; neutrophils 50 ~ 75%; eosinophils 2 ~ 4%;
basophils 0.5 ~ 1%; lymphocytes 20 ~ 40%; and monocytes 3 ~ 8%. The proportion depends
Table 2.1 Sizes and shapes of blood cells
Size and shape of blood cells

Diameter [μm]

Red blood cells (Erythrocytes)

6 ~ 8 (Thickness: 1 ~ 3)

White blood cells (Leukocytes)

7 ~ 20

Spherical

Platelets

2~5

Fragments
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Shape
Biconcave disk

on the gender, age, and condition of the body. The numbers of leukocytes can be increased
by disease. The size of each type of leukocyte is 7 ~ 9 µm for neutrophils, 9 ~ 10 µm for
eosinophils, 7 ~ 9 µm for basophils, 7 ~ 9 µm for lymphocytes, and 9 ~ 12 µm for monocytes.
The size of leukocytes based on the type is summarized in Table 2.2.
The normal pH of whole blood is 7.35 ~ 7.4 and viscosity is 3.0 cP at 37 °C. However,
the viscosity depends on the hematocrit, the ratio of red blood cells to whole blood, and the
velocity of the blood flow. Figure 2.1 shows a scanning electron microscope (SEM) image of
human blood.
Table 2.2 Size of leukocytes
Leukocyte types

Size [μm]

Neutrophil
Eosinophil
Basophil
Lymphocyte
Monocyte

7~9
9 ~ 10
7~9
7~9
9 ~ 12

Platelets
Erythrocytes

Leukocytes
http://visualsonline.cancer.gov

Figure 2.1 Circulating blood cells, erythrocytes, leukocytes, and platelets, in a human body [4]
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2.2.2

Biological Properties and Functions

Human blood has two main functions, transportation and defense. Transport is done by
red blood cells and plasma. Defense is carried out by white blood cells and serum [5]. Red
blood cells transport oxygen and carbon dioxide through the body. One red blood cell can
contain three hundred thousand molecules of hemoglobin. Since a single hemoglobin can
carry four molecules of oxygen, one red blood cell can transport 1.2 million molecules of
oxygen. Plasma delivers or removes various ions (Na+, Ca2+, HCO3-, etc), glucose, amino
acids, other organic acids, cholesterol and other lipids, hormones, urea and other wastes.
White blood cells protect the body from infection or any other foreign materials. Platelets
stop bleeding by solidification of the blood, known as coagulation or clotting.
The blood also maintains the pH in the rage 6.8 to 7.4 to avoid cell damage and maintains
the body temperature; a pH below 6.8 or a pH above 7.8 will cause serious damage. Human
blood cells are derived from hematopoietic stem cells in the bone marrow. Figure 2.2 shows
the development of blood cells from a blood stem cell. A healthy adult produces more than
1012 hematopoietic cells to produce any necessary blood cells every day.

Figure 2.2 Development of human blood cells from a human blood stem cell in the bone
marrow [4]
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2.3 The Immune System in the Human Body
The immune system can protect bodies from bacteria, viruses, and parasites, which have
never been encountered before. The body can produce over 108 distinct antibodies and more
than 1012 T-cell receptors with very specific distinguishable abilities [6]. The immune system
has two parallel but interconnected systems, the humoral and cellular immune responses.
The humoral immune response works by antigen-antibody reactions. An antibody,
immunoglobulin, functions as a recognition element that binds to foreign molecules and
signals foreign invasion. The antibody is secreted by plasma cells which are originally
derived from B cells. The antigen is any foreign macromolecule which has a specific affinity
for an antibody. Thus, each antigen binds selectively to a specific antibody. Therefore, the
humoral immune response, antigen/antibody reaction is not a whole macromolecular event,
but an event at a particular site on the antigen.
The cellular immune response is primarily driven by cytotoxic T lymphocytes, called
killer T cells, which kill cells displaying foreign motifs on their surface. Helper T
lymphocytes stimulate the differentiation and proliferation of appropriate B cells and
cytotoxic T cells, contributing to both the humoral and the cellular immune responses.
Specific receptors that are expressed on the surface of the T cells mediate the cellular
immune response. Originally, all of the cells of the immune system are derived from the
hematopoietic stem cell and differentiated from one type of stem cell, shown in Figure 2.2.
Despite the immune system, tumors are capable of evading immune recognition [7].
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2.3.1

Lymphocytes and the Immune Response

Three types of lymphocytes, which are differentiated from hematopoietic stem cells, play
a major role in the immune system: B cells, T cells, and natural killer cells. In the peripheral
blood, B cells are 10-20% of lymphocytes, T cells account for 70-75%, and natural killer
cells (NK cells) comprise 10-15%. Most of the lymphoid cells in the peripheral lymphoid
tissues are B cells lineage [3, 6, 8].
B cells or B-lymphocytes, which are developed in the bone marrow, produce antibodies
and memorize the signal of antigen to reproduce. When contacting an antigen, B-cells
differentiate into the plasma to secrete antibodies or into B-memory cells. B cells need to
cooperate with T-cells for an efficient antibody response and immune defense.
T cells or T-lymphocytes, which are developed in the thymus, differentiate into two
classes: CD4-positive T-lymphocytes (CD4+ or helper T cells) and CD8-positive Tlymphocytes (CD8+, cytotoxic, killer, or suppressor T-cells). Helper T cells recognize foreign
antigens, stimulate B cells to produce antibodies, and contribute to the development of killer
T cells. Killer T cells react with foreign antigens, take cell-mediated immune response, and
control the proliferation of other T-cell subsets. Figure 2.3 shows the immune response of T
lymphocytes by the process of antigen presentation by macrophages.
Natural killer cells do not need to recognize a specific antigen (natural immunity) and are
capable of killing some tumor cells. However, the physiological function of NK cells and the
mechanism of removal for certain tumor cells or other virally infected cells is still not well
understood.
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Figure 2.3 Immune response by a T lymphocyte with antigen presentation process [2]

2.3.2

Antigen/Antibody Reactions

An antigen (Ag) or immunogen is any substance that induces the formation of antibodies
and causes an immune response, when introduced parenterally into an animal. Alternately, an
antigen, also known as an antibody generator, is any molecule which can stimulate antibody
generation or generate an immune response [9].
An antibody (Ab) or immunoglobulin (Ig) is a protein that can be used by the immune
system to identify foreign objects. Antibodies, or immunoglobulin, have two large chains and
two small light chains as a one unit. Antibodies can be classified into three types of structures
based on the number and structure of the chains - one unit of two coupled heavy and light
chains (monomers), two units of coupled chains (dimers), and five units (pentamers).
Moreover, based on the isotypes of the two heavy polypeptide chains, immunoglobulin can
also be divided into five subclasses IgA (alpha), IgD (delta), IgG (gamma), IgE (epsilon), or
IgM (mu). There is a particular region which can bind with an antigen, the fragment antigen

23

binding, or Fab, which is located at the end of each light and heavy chain couple. [10, 11]
The basic structure of an antibody is shown in Figure 2.4.
For the binding of antigen-antibody pair, the following conditions are required. First,
complementarity and specificity of the antigen and antibody are required conditions for the
reaction. Second, the antigen and its specific antibody need to be physically close together
(less than 5 nm.) Third, the affinity between the antibody and its particular antigen should be
high. Fourth, the number of multivalent sites needs to be approximately the same. Fifth, the
concentration of antigens and antibodies needs to be suitable. Sixth, a proper environment is
necessary.
The fundamental concept of antigen-antibody reaction is a lock and key fit; each antibody
reacts with only its specific antigens. However, there is a cross reactivity; an antibody can
bind not only with its specific antigen but also with an antigen which has a structure similar
to the specific antigen.

(a)

(b)

Figure 2.4 (a) a basic structure of immunoglobulin [11] and (b) ribbon drawing of a antibody
(IgG) [12]
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Antigen-antibody binding is a physio-chemical reaction. All forces except covalent
binding contribute: hydrogen bonds, electrostatic forces, van der Waals bonds, and
hydrophobic bonds. The antigen/antibody reaction is reversible under certain conditions,
such as pH, temperature, ion concentration, or agitation.
Antigen-antibody binding is a two step process. The first step is an encounter complex
step which means specific antigen and antibody molecules simply encounter each other and
form an encounter complex: Ag + Ab  AgAb. The second step is the cell binding step,
which needs electrolytes (Na, Cl, H, Mg, K, etc.): AgAb  C. Ag is antigen, Ab is antibody,
AgAb is the encounter complex stage, and C is the bound stage.

2.4 Transportation of Blood Cells in the Human Body
2.4.1

Fahraeus Effect and the Marginal Plasma Layer

The hematocrit, the ratio of red blood cells to whole blood, is very important in defining
the behavior of the blood cell flowing in a vessel. The hemacorit depends on the tube
diameter, which is called the Fahraeus effect, shown in Figure 2.5. In the range of 15~500
μm diameter of capillaries, the hematocrit in a capillary tube, HT, is smaller than that in the
feed and discharge tubes.
The magnitude of the Fahraeus effect decreases as the tube diameter decreases and the
maximum effect occurs for approximately a 15~20 μm diameter tube. Figure 2.6 shows the
Fahraeus effect based on the capillary tube diameter.

25

Figure 2.5 Schematic illustration of the Fahraeus effect with arbitraily assumed velocity of
cells, Vc, and velocty of the plasma, Vp. (Black dots indicate red blood cells) [13]

Figure 2.6 Fahraeus effect as a function of the capillary diameters (HT: Tube Hematocrit, HD:
Discharge Hematocrit) [13]
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Figure 2.7 The Fahraeus-Lindquist effect [13]
Due to the Fahraeus effect, decreasing the tube diameter decreases the viscosity of the
blood which is called the Fahraeus-Lindquist effect (see Figure 2.7.) The relative apparent
viscosity of the blood decreases as the tube diameter deceases until a tube diameter of
aprroximately 4-6 µm.
Red blood cells tend to flow at the core of a channel due to their size, shape, and
deformability. Due to this axial accumulation of red blood cells, a thin cell free layer, also
called the plasma layer, is created in the channel. The thickness of the plasma layer is a
function of the tube diameter and the hematocrit. Due to the marginal plasma layer, the
viscosity at the core of a channel is higher than the viscosity near the wall.
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Marginal zone theory is used to characterize the Fahraeus-Lindquist effect. From
marginal zone theory, viscosity is a function of the hematocrit, blood velocity, plasma layer
thickness, and tube diameter. The thickness of the plasma layer can be estimated [1, 13-15].
2.4.2

Effect of Erythrocyte or Leukocyte Rolling

Erythrocytes tend to flow at the fastest position in a vessel along the center axis. This
axial accumulation creates plasma skimming or plasma layer in a vessel or in a channel.
The plasma layer may not help the lateral migration of the leukocytes, but the axial
accumulation of erythrocytes forces the leukocytes to migrate toward the wall and helps the
leukocytes encounter and roll along a channel wall [16-20].
2.5 Circulating Human Breast Cancer Cell and EpCAM
Circulating tumor cells, CTCs, exist at the early stage of tumor development and are very
rare events: there are just a few CTCs in 1 mL of blood [21-23]. Even through some CTCs
die during migration, other CTCs stay alive for several years and may cause macrometastases
[24]. After the earliest stage of tumor development, the tumors grow rapidly [25]. Therefore,
early stage cancer diagnosis is very important and detecting CTCs may be a key to early
diagnosis.
EpCAM (Epithelial Cell Adhesion Molecule), also known as GA733-2, KSA, CD326,
ESA, or 17-1A antigen, is one of the powerful biomarkers for breast cancer because in a
peripheral blood CTCs express the EpCAM antigen. CTC detection can give a great
opportunity for easy and simple diagnosis at an early stage. EpCAM can be used as a
biomarker for other tumor cells [26-28].
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2.6 Review of CTC Separation or Capture in BioMEMS
BioMEMS technology has been developed for cell separation or capture applications
because it offers the advantages of a small sample volume, portability, low cost, easy sterility,
and potential integration. Cell separation using BioMEMS can be classified as size-based,
optically-based, or affinity-based approaches. Each method has advantages and
disadvantages, such as sensitivity, flow rate, or recovery rate. Therefore, reviewing the
current technology is necessary for CTC detection or capture research.
2.6.1

Size-Based Approach

Size based CTC separation was tried for cell separation using the size differences
between CTCs and human blood cells. However, the sample required very high pre-dilution
and have purity issues. Not only the target cell but also other blood components were
captured or trapped.
Mohamed, et al. (2004) demonstrated separation of metastatic cancer cells from
peripheral blood using parallel arrays of posts as obstacles [29]. The distance between the
parallel channels and the depth of the channels was from 2.5 ~ 20 μm for different size of
cells. Figure 2.8 (a) is an SEM (Scanning Electron Microscope) image of the micro obstacles.
Separation took 2 ~ 3 hours for 2 mL of whole blood, without dilution. However, the
separation efficiency was not clearly indicated and recovering the separated cells could be an
issue.
Sethu et al (2006) introduced separation of leukocytes from whole blood using a micro
diffusive filter [30]. Figure 2.8 (b) shows the design. The operating flow rates were 5, 7, and
12 μL/min and more than 10% of leukocytes passed through sieves at 7 μL/min.
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(a)

(b)

(c)
Figure 2.8 Size based separation using (a) micropost obstacles [29], (b) micro diffusive filter
[30], and (c) 3D microfilter separation [31]

Zheng et al (2010) fabricated a 3D microfilter device for CTC capture from blood [31].
The recovery rate was acceptable (85.6%) with a very high flow rate (1.8 ~ 3 mL/min).
Figure 2.8 (c) shows the design and captured CTC on the filter. However, the 3D microfilter
deivce required 9 X sample dilution and limited sample volume (up to 1 mL) to avoid
clogging with leukocytes.
2.6.2

Optically-Based Approach

A micro fluorescent activated cell sorter, μFACS, which is based on fluorescence
technology, was demonstrated by Wolff et al (2003) to sort fluorescent latex beads from
chicken red blood cells [32]. Figure 2.9 shows the simple concept of the μFACS. The flow
rate was 0.11 μL/sec which is very high compared to other methods. However, it was not
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Figure 2.9 Micro fluorescent activated cell sorter [32]

demonstrated with real biological material and also it was not tested or certified for rare cells
such as CTCs in whole blood.
2.6.3

Affinity-Based Approaches

Affinity-based cell separation or capture uses the immune response, or antigen/antibody
reaction. The affinity-based methods can be divided into antibody coated magnetic attraction
or antibody functionalized surfaces. Furdui and Harrison (2004) introduced a magnetic
attraction method using antibody coated magnetic beads [33]. In Figure 2.10 (a), a Y-channel
microfluidic device separated T cells from whole blood with to a 40% efficiency at a 3
μL/min flow rate.
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(a)

(b)

Figure 2.10 Magnetic separation method by (a) Furdui and Harrison`s Y-channel device to
separate T cells from blood using magnetic beads [33] and (b) leukocytes separation from red
blood cells on a planar surface [34]

Inglis at al (2004) showed that separation of leukocytes from red blood cells on the planar
magnetic stripes. In the Figure 2.10b, the target cells were labeled with CD45 conjugated
nanobeads and captured at a velocity of 110 μm/s on stripes of different angles [34].
Cell separation using antibody functionalized polymer surfaces was demonstrated by
Feng, et al. (2003) [35]. MCF-7 cells were captured on an anti-EpCAM coated polymer
channel at a 2 mm/s velocity which was selected as an optimal velocity by modeling the
antibody-antigen reaction..
Nagrath, et al. (2007) showed isolation of CTCs from human whole blood using a silicon
CTC chip containing anti-EpCAM coated microposts [36]. The maximum recovery rate was
65% with 1 mL/hr flow rate. Figure 2.11 (a) shows the experimental set up, the CTC chip,
and the microposts.
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(a)

(b)

(c)

(d)

Figure 2.11 CTC isolation using antibody coated micro device with (a) microposts etched
CTC chip [36], (b) multiple sinusoidal channels [37], (c) Herringbone shape PDMS device
[38], and (d) Cell capture-agent-coated nanostructured silicon substrate with chaotic mixing
chip [39]

Adams, et al. (2008) introduced a polymer high throughput cell capture device using 51
parallel sinusoidal channels to increase the flow rate [37]. The recovery rate was over 95% at
a 32 μL/min flow rate. The simple geometry of the device and concept are shown in Figure
2.11 (b).
Stott, et al (2010) used polydimethylsiloxane (PDMS) herringbone shape chip to generate
microvortices [38]. The capture efficiency was increased by 26% compared to the CTC chip
from Nagrath, et al. but the flow rate was low, < 2.5 mL/hr. Figure 2.22 (c) shows the device
and herringbone shapes on the channel top.
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Wang, et al (2011) introduced cell capture-agent-coated nanostructured silicon substrate
with a chaotic mixing chip [39]. The nanostructure increased the capture efficiency and the
chevron shape chaotic mixer improved the encounter ratio. The device and nanostructures are
shown in Figure in 2.11 (d). The recovery rate was 95% but the flow rate was 1 mL/hr which
is not sufficient for clinical uses.
Affinity-based separation method has a high recovery rate. However, the maximum flow
rate is not acceptable for clinical use. It would take over 4 hours to test a 7.5 mL sample
volume even with the fastest design.
2.6.4

Other Approaches

Hydrophoretic filtration was demonstrated to separate white blood cells from red blood
cells based by Choi, et al. (2007) [40]. The flow rate was 1 μL/min for leukocyte isolation
which gave about 58% of the isolation efficiency and a recovery rate of over 70%. See
Figure 2.12 (a).
Shevkoplyas, et al. introduced a very interesting method of autoseparation of leukocytes
from whole blood [20]. The principle of the autoseparation was leukocyte margination and
plasma skimming which lead to leukocyte rolling in human blood vessels. The depth of the
device was 10.3 μm which was similar with average diameter of leukocyte. Most of the
leukocytes were pushed to the nearest sidewall because flexible erythrocytes tend to flow at
the core of the channel, collide with leukocytes, and force the leukocytes to migrate laterally.
Even through the flow rate was very low (approximately 0.54 nL/s for a 70 μm wide channel
inlet), this approach may be valuable for the design of a cell separation device. Figure 2.12 (b)
shows the location of the leukocytes in the channel and the device design.
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Moon, et al. (2011) developed a cell separation device using multi-orifice flow
fractionation (MOFF) and dielectrophoresis (DEP) [41]. The MOFF can relocate
microparticles or cells laterally because of hydrodynamic inertial force. The DEP force
moves the target cell only because only the large target cells take the sufficient attractive
force. The device could reach 126 mL/min flow rate and the recovery rate was 75.81%.
However, it required very high low concentration of blood cells. The concentrations of
erythrocytes and leukocytes were less than 1% and 0.01% respectively compare to
concentration of normal human blood. Figure 2.12 (c) shows the device and the separating
target cells in the device.
2.6.5

Comparison of Current Research Methods

Cell separation technologies using BioMEMS have been developed by many researchers.
However, it is still a question, especially for rare cells such as CTCs, whether any method or
device can be suitable for a portable device or for a clinical use or not. The issues are
recovery rates and low flow rates which makes the micro devices unacceptable for use at the
point-of-care (POC.) The affinity-based approaches have high recovery rates compared to
other methods but the flow rates are still an issue. Since the flow rate is not sufficient for
clinical use and not applicable for a portable device, it is necessary to solve the problems.
Table 2.1 compares the flow rates and recovery rates of different cell separation approaches
using BioMEMS technology.
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(a)

(b)

(c)
Figure 2.12 Leukocyte separation using (a) hydrophoretic filtration [40], (b) lateral migration
of leukocyte [20], and (C) MOFF with DEF [41]
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Table 2.3 Comparison of flow rates and recovery rates of BioMEMS devices
Approaches or
Principle
Size based

Optical based

Affinity based

Hydrophoretic
filteration
Axial accumulation
of erythrocytes
MOFF with DEP

Micropost obstacle arrays

Recovery
Rate
Low

Micro diffusive filter

Medium

7 μL/min

3D microfilter (9X dilution)

High (86%)

3 mL/min

Fluorescent label

N/A

Low
(0.11 μL/sec)

Magnetic beads

Low (40%)

3 μL/min

Magnetic stripes

Low

Low

Antibody coated micro posts

Medium (65%) 17 μL/min

Multiple sinusoidal channel

High (95%)

32 μL/min

Nanostructure with chaotic mixer

High (95%)

17 μL/min

Slanted obstacles

Low (58%)

1 μL/min

Daughter channels

Low

3 μL/min

hydrodynamic inertial force
and DEP force (>100X dilution)

High (76%)

126 μL/min

Basic Method or Technology
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Flow Rate
High

2.7 Commercial Technologies for CTC Detection
Commercialized products for CTC detection are CellSearch (Veridex, Raritan, NJ, USA,)
OncoQuick (Greiner BioOne, Frickenhausen, Germany; Greiner Bio-One, Inc., Longwood,
FL, USA,) AdnaTest (AdnaGen AG, Hanover, Germany; OncoVista, Inc., San Antonio, TX
USA,) OncoCEE (Biocept, Inc., San Diego, CA, USA,) and On-Q-ity CTC Chip (On-Q-ity,
Waltham, MA, USA) [42-45]. Table 2.4 shows the comparison of these CTC detection
technologies.
CellSearch is the only instrument approved by the U.S. Food and Drug Administration`s
(FDA) for metastatic breast, colon, and prostate cancer. It uses anti-EpCAM coated magnetic
beads (iron particles) to separate CTCs from whole blood (7.5 mL) and detect the CTCs
using fluorescent techniques with CK+, DAPI+, and CD45-. The recovery rate for high
EpCAM expressing cells is over 75% but it was decreased to 42% for low EpCAM
expressing cells. The recovery rate for 10 spiked CTCs was 100% with 30% initial sample
preparation error [42-45].
OncoQuick uses density gradient centrifugation for CTC separation and an immunobased technique for CTC detection. The recovery rate is 72 ± 18% (56~92%) from whole
blood (15 ~ 30 mL) according to a manual from the company [45-47].
AdnaTest is undergoing FDA approval, and a Phase II clinical trial protocol is finalized.
It uses immunomagnetic beads with anti-EpCAM or 2 antiMuc-1 for CTC separation from
whole blood (2 x 5 mL), followed by molecular analysis using reverse transcriptasepolymerase chain reaction (RT-PCR.) The separated CTCs are lysed and semi-quantitative
RT-PCR performed with three epithelial cell associated messenger RNAs (MUC1, HER2,)
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and the surface glycoprotein GA733-2 to obtain the number of CTCs. It could detect 31~69%
from metastatic breast cancer patients [48, 49].
OncoCEE and On-Q-ity use antibody coated micro posts in a microchannel to separate
the CTCs and identify the CTCs using fluorescence technique with CK, CD45, and DAPI.
On-Q-ity additionally uses the size difference between CTCs and blood cells by using the
gaps between the posts. On-Q-ity separates CTCs from 20~30 mL of whole blood without
pre-treatment of the sample unlike OncoCEE which uses centrifugation. The recovery rate
for high EpCAM expressing cells was >75% for both CTC chips. The recovery rate was for
low EpCAM expressing cells was less than 50% for the Onco CEE CTC chip and higher than
50% for the On-Q-ity CTC chip. In the case of ten spiked CTCs, the recovery rate was less
than 50% for both CTC chips [43, 50, 51].
Table 2.4 Comparison of commercial products
Brand

Method

Detection/
Identification

Sample
Volume

Recovery Rate

CellSearch

Immunomagnetic
bead

Fluorescence

7.5 mL

>75% for high EpCAM cell
(<50% for low EpCAM cell)

OncoQuick Density gradient

Immuno-based 15~30 mL

>70% (from catalog)

AdnaTEST

Immunomagnetic
bead

Molecular
analysis

2 x 5 mL

31 ~ 69% for clinical
detection

OncoCEE

Immuno micro
channel with posts

Fluorescence

10 mL

>75% for high EpCAM cell
(<50% for low EpCAM cell)

On-Q-ity

Immuno micro
channel with posts

Fluorescence

20~30 mL

>75% for high EpCAM cell
(>50% for low EpCAM cell)

2.8 Direction of Future CTC Capture Devices
Current technologies for CTC capture were summarized and commercial products were
introduced, but do not meet needs for clinical use and point-of-care (POC) applications. The
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flow rate, recovery rate, and purity are still under the requirements. Size-based approaches
could not satisfy the purity issues and requires pre-treatment of sample. Affinity-based
approaches have a limited flow rate. Commercialized products have limited the flow rates
and capture efficiencies. None of the approaches or products can be used for portable or POC
application. The limitations of current methods include low flow rates, low recovery rates,
low purity, and the need for pre-treatment of the sample that must overcome. Moreover,
molecular analysis needs to be performed downstream to eliminate false-positive results and
to obtain more specific and detailed information after target cell capture.
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CHAPTER 3: DESIGN AND SIMULATION

3.1 Design Concept for a High Flow Rate Device
3.1.1

Sample Volume for Circulating Tumor Cell Detection

Circulating tumor cells, CTCs, in human peripheral blood are very rare events, 1 ~ 2
CTCs in 1 mL circulating blood. This low concentration of CTCs requires a large sample
volume to ensure reliable detection. The typical sample volume for blood-based tests requires
7.5 mL to detect early stage cancer or to decide the probability of survival [1-4]. Current
microdevices for cell capture usually operate at very low flow rates for maximal recovery
rate. Therefore, to reliably detect CTCs in normal sample volumes of whole blood in a
reasonable time (10 minutes), design of high a speed micro device is essential and a
significant challenge.
3.1.2

Design Target and Constraints

Design of a capture device should consider the function, fabrication method, and
applications. The target is a high flow rate device for fast target cell capture from a relatively
large volume of whole human blood for fast diagnosis or portable applications. The inlet
flow rate is determined as 0.75 mL/min (12.5 mm3/sec) which will process the required
sample volume (7.5 mL) in ten minutes. However, cell capture using antigen/antibody or
aptamer reactions needs a low velocity to have a sufficient duration for binding to occur. The
linear velocity for cell capture was selected in a range of 1~2 mm/sec based on previous
studies with EpCAM [5, 6]. Therefore, the linear velocity in the capture area, a
functionalized microchannel, has to be 1~2 mm/sec for maximum cell capture even though
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the flow rate at the inlet of the device is 0.75 mL/min. Moreover, the size of the channel
cross-section has to be minimized to maximize the encounter rate and it also needs to be
large enough to avoid clogging. The mean diameter of CTCs in human blood is 30 μm in
some cases of patients [7]. The diameter of CTCs is usually 10 ~ 30 μm. Therefore, one
dimension of the channel (width or depth) should be at least 30 μm to avoid blockage.
Maximizing the encounter rate is one of the main objectives, because contact between the
target cells and the functionalized channel walls is the first step in the antigen/antibody
reaction. However, cells tend to flow at the center of the channel because of the parabolic
velocity profile in laminar flow and the cell-free plasma layer which is formed in blood flow
[8]. Moreover, lateral movement of the target cells is not easy to predict or control in a
straight microchannel. A solution for these complicated issues is manipulating the velocity
profile. If the velocity profile is not a parabola in a laminar flow, the target cells can be close
to the channel wall and the encounter rate will be maximized. Manipulation of the velocity
profile can be realized by adding another narrow channel or adding a small port in the main
channel. Post arrays in a microchannel can change the velocity profile and enlarge the
surface area, but the posts will reduce the cross-sectional area and lead high mean velocity to
obtain high flow rate.
The velocity vector of the fluid can be changed if there is more than one outlet to a single
channel. The velocity profile at a near channel wall in a single channel and a channel with
narrow port are shown in Figure 3.1(a) and 3.1(b) respectively.
The size of the narrow gap or port needs to be controlled to keep the target cells in the
capture, or main, channel. Otherwise, the target cells may escape through the narrow gap or
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(a)

(b)
Figure 3.1 Velocity profile a near wall (a) in a single channel without port and (b) in a single
channel with a port

the port. Moreover, the magnitude of the velocity or pressure gradients between the main
channel and the gap and the pressure drop in the narrow gap or side channel need to be
considered. The pressure drop governs the flow rate in the narrow gap, and the flow rate
dominates the lateral component of the fluid velocity vector. A high lateral velocity
component forces the target cells to deform and flow out through the gap even if the cell is
larger than the gap.
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A conceptual design is shown in Figure 3.2. Using a narrow gap will decrease the volume
of the sample in the main channel and increase the concentration of the target cells since
other components, including plasmas, platelets, and red blood cells, in the blood should be
filtered out through the narrow side channels. Therefore, a high flow rate can be realized with
a high recovery rate. From an application point of view, a smaller device, with a small
footprint, is preferred.
A small device for cancer cell capture can be integrated in a blood collection tube or
needle and it can also be combined with multi well titer plates. Therefore, the length of the
device needs to be less than 10 cm to be an integrated device of the blood collection tube.
Indeed, one of proposed targets of this project is a portable device for cancer diagnosis.

Figure 3.2 Initial design concept – Main channel with narrow side channels
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Lt: Total length of the main channel
Lv: Length of variable depth section
W: Width of main channel
S: Width of side channel

c: Depth of main channel after Lv
h: Initial depth of the variable depth section
g: Depth of side channel
θ: Angle of variable depth section

Figure 3.3 Initial design approaches and parameters (a) top view of the main and side
channels, (b) side view of the channels, and (c) front view of the channels

Fabrication of the device introduces multiple constraints on the design. The width of the
main channel needs to be minimized to avoid deformation during thermoplastic fusion
bonding. The depth of the main channel inlet should be large enough to minimize the inlet
velocity with a 0.75 mL/min flow rate. The width of the side channels should have enough
space for the milling process since the milling of the side channels on the mold insert need to
be stepped, with different heights from the main channel to achieve a narrow gap.
There are conflicting requirements for the cross-section and the depth or width of the
main channel. The inlet of the main channel should be large enough to minimize the inlet
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velocity, but the main channel also needs to be small enough to maximize the encounter rate
of the cells with the wells.
A variable cross-section for the main channel is one solution for achieving a high flow
rate with a minimal inlet velocity in the entrance region and realizing a low depth for the
main channel after the variable depth channel section to obtain the maximum encounter rate.
Figure 3.3 shows a configuration with a variable depth main channel. It can also be used to
control the lateral velocity of the side channel. The angle (θ) governs the pressure and
velocity in the variable section.
3.2 Determination of the Baseline Channel Sizes
3.2.1

Side Channel Design

As a blood cell filter and velocity profile manipulator, the dimensions of the side channel
have to be carefully determined to avoid the loss of the target cells and device rupture. The
depth of the side channels should be small enough to avoid any loss of the target cells. The
target cells for evaluating circulating human breast cancer diagnosis is the MCF-7 cell. The
diameter of the MCF-7 cell is normally larger than 15 μm. Figure 3.4 shows the size of a
cultured MCF-7 in a hemacytometer. The average size of circulating human breast tumor
cells is around 30 μm in diameter [7]. Cells can deform under high pressure to pass through
narrow gaps. Therefore, the depth of the side channels should be 10 μm or less.
The lengths of the side channels are determined by the resulting pressures and flow rates
which are dependent on the angle of the variable depth section in the main channel. Multiple
lengths of main and side channels were simulated using Fluent v6.3 (ANSYS, Inc.,
Canonsburg, PA, USA.)
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Figure 3.4 Size of the MCF-7 cell line (Two MCF-7 cells are shown in the right picture.)

The reservoirs for the side channels were located at the end of the side channels to obtain
an even pressure distribution when the side reservoir works as suction port. The entrance
region of the main channel has high pressure and a high flow rate, which decreases along the
length of the main channel.
3.2.2

Main Channel Design

The depth of the main channel should be small enough to maximize the encounter rate.
One of the possible options is 30 μm for a maximum encounter and to minimize cell clogging
issue. Conversely, it should be large enough to minimize the pressure drop at high flow rates.
Therefore, a variable depth with a deeper entrance region and a shallower capture region
were applied. Multiple depths of the main channel entrance were simulated to estimate the
pressure variation and the flow rate (or maximum velocity) along the main channel. A wider
main channel allows a higher flow rate and lower pressure drop. However, the wider channel
can deform more during thermal bonding. Consequently, the width of the channel cannot be
larger than 500 μm. Due to deformation, a 300 or 400 μm width of the main channel was
chosen. Even though the width of main channel was 300 ~ 400 μm, the length between
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contact points which support the cover slip during thermal bonding of the main channel can
be closer to one millimeter since the support structures are outside of the side channels,
which are connected to the main channel.
The length of the variable depth section is very critical for the control of the pressure, the
flow rate, and the velocity vector throughout the device. The length and the initial depth of
the variable depth section determine the angle (θ) of the variable depth section. To achieve
constant pressure at the side channel along the main channel, the length of the variable
section needs to be large enough or the angle (θ) needs to be small to avoid a sudden velocity
increase.
3.2.3

Encounter Rate and Duration Time

Encounter is the first step in an antigen/antibody reaction. To maximize the encounter
rate, the size of the main channel and the velocity of the target cell need to be considered. A
small channel and high velocity give a high encounter rate because cells pass by a large
number of receptors and have a short distance to travel to them. However, a high velocity
reduces the time during which the binding reaction can take place. Therefore, 30 μm was
chosen for a high encounter rate, and less than 2 mm/s mean velocity was chosen as the
target velocity. The target flow rate of the main channel outlet was already determined since
the main channel was 300 ~ 400 μm wide with a 30 μm depth and less than a 2 mm/s mean
velocity. The flow rate in the main channel outlet needed to be less than 0.024 mm3/s or 0.2%
of the inlet flow rate. Long side channels or a second set of side channels after the first
section side channels can give the required low flow rate if the outlet flow rate after the first
side channel is higher than the target flow rate. One design option for the high flow rate
device for CTC capture is shown in Figure 3.5.
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Drain Reservoir

Main Channel
Inlet Reservoir

Side Channel
Variable Depth of Main
Channel
(b)

(a)

Figure 3.5 Design of the high flow rate device (a) the mold insert (b) half of the PMMA
device

3.3 Reservoir Design
Design of the inlet reservoir is very important, especially for rare cell capture, because
target cells can be lost or clogged at the inlet reservoir if there is large misalignment between
the center of the capillary and the reservoir center. Missing a single target cell can seriously
affect the diagnostic result of the CTC capture due to the rarity the CTCs. For example, loss
of one target cell can give more than 10% error for a 7.5 mL sample since the critical number
of CTCs is 5 in 7.5 mL.
3.3.1

Dead Volume and Pressure Drop

The reservoir, which connects the capillary and channel, usually creates a dead volume
which may cause vortical flow in the reservoir. The dead volume may produce cell loss or air
bubbles. Trapped air may interfere with cell capture or lead to inaccurate control and slow
response of the sample flow. The reservoir is also one of the sources of higher pressures due
to the dramatic geometry change from a macro capillary to a microchannel [9, 10]. If a
mismatch between the reservoir core and a capillary tube connection hole is large, cell
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transportation cannot be done properly because the capillary can be partially or totally
blocked. To avoid unwanted cell trapping or cell clogging, the hole needs be located at the
center of the reservoir with minimal burrs.
3.3.2

Semi-Automatic Positioning of Reservoir Core for Drilling

Drilling of the reservoir is also very important for rare cell experiments because improper
drilling will increase the pressure drop and target cell loss. Drilling should minimize the burr
and the drilled hole needs to be located on the centerline of the reservoir. To locate the hole
at the center of the reservoir, a drill guide was designed. The guide semi-automatically helps
to locate the drill bit at the center of the reservoir. Once the tip of the bit is inserted in the
drill guide hole, the drill bit is pushed toward the center by the polymer device. A reservoir,
mold insert, hot embossed polymer, and drilled hole are shown in Figure 3.6.

Drilled hole

Drilling guide hole
Drilling guide
Reservoir structure

Reservoir
(a)

(b)

(c)

Figure 3.6 Reservoir design and drilling for reduced cell loss (a) mold insert, (b) hot
embossed PMMA, and (c) center drilled hole with less than 10 μm mismatch

3.4 Simulation of a High Flow Rate Device
It is essential to predict the fluid behavior including velocity vectors, path lines, flow
rates, and pressure in the channel for optimum design. Computational fluid dynamics (CFD)
was used to estimate the performance and to optimize the device dimensions before actual
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fabrication. The Fluent program (Fluent v6.3.26, ANSYS, Inc., Canonsburg, PA, USA) was
used for the simulations. Gambit (Gambit v2.46, ANSYS, Inc., Canonsburg, PA, USA) and
Tecplot (Tecplot v360, Tecplot, Inc., Bellevue, WA, USA) were used for meshing and post
processing.
Two baseline configurations were initially studied, as shown in Figure 3.7. The first had a
constant depth main channel and the second incorporated a variable depth main channel. A
parametric study was used to determine the final dimensions (depth, length, width of
channels.)

(a)

(b)
Figure 3.7 Baseline configurations for simulation: (a) Uniform depth main channel and (b)
Variable depth main channel
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3.4.1.

Meshing and Boundary Conditions

Meshing was done using Gambit. The mesh type was hexahedral cells and it was
manually generated. The size of each cell was 10 μm in the x- and y-directions and 2 ~ 10
μm in the z-direction. The maximum cell size was 10 μm on all sides. The cell size was small
enough to obtain general information about local pressures and velocities. Typical hexahedral
cells and the reference point with X-, Y-, and Z- directions are shown in Figure 3.8. Water
was used for working fluid and all other unmeshed surfaces were defined as solid walls
except one inlet and three outlet surfaces.
A velocity inlet was used to establish the inlet conditions and give a constant inlet flow
rate. A pressure outlet was used to calculate the flow rate based on the pressure differences at
each outlet, including the side and main channels. All outside surfaces were set to
atmospheric pressure.

Z

Reference
Point

X

Y

Figure 3.8 Typical hexahedral 3D mesh used for simulations
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Inlet velocity was selected based on the inlet cross section area to provide 0.75 mL/min
or 0.075 mL/min to check the flow rate effect. The Fluent solver was 3ddp which runs a
three-dimensional, double-precision solver. Convergence criteria for all residual variables (x-,
y-, and z-velocities and continuity) were given 10-7 to get accurate results. To check the
effect of the mesh size, multiple mesh sizes were simulated. The error for different meshes
was tested for pressure and velocity. Results for the medium and fine meshes were very
acceptable. One example of residual monitoring for convergence as a function of the number
of iterations and the mesh sensitivity are shown in Figure 3.9 and Figure 3.10, respectively.
Mesh size effects were tested by comparing the velocity and pressure from very coarse,
coarse, medium-coarse, medium, and fine mesh conditions.
3.4.2.

High Flow Rate Device Version One (HFRD1)

Simulations were performed for the two baseline designs in Figure 3.7. Design of a
constant depth main channel, Figure 3.7 (a), was simulated for the flow behavior in the main
channel with side channels and the high flow rate application.
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Figure 3.9 Residual monitoring with iterations

Medium-coarse mesh
Medium mesh
Fine mesh

Coarse mesh
Very coarse mesh

(a)

Fine mesh
Medium mesh

Medium-coarse mesh

Coarse mesh
Very coarse mesh

(b)
Figure 3.10 Mesh size effects on (a) velocity and (b) pressure: very coarse mesh (43,600
cells), coarse mesh (222,400 cells), medium-coarse mesh (410,100 cells with non-uniform
mesh shape), medium mesh (356,000 cells), and fine mesh (818,000 cells)
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Simulations of the variable depth main channel, Figure 3.7 (b), werealso computed to
minimize the maximum pressure and to maximize the encounter rate of the target cells with
the wall with minimum flow velocity at the main channel outlet. The high flow rate devices
version one (HFRD1) had 10 μm deep side channels. The working solution was water.
3.4.2.1

Constant Depth Main Channel

For a constant depth main channel, multiple cases, C1~C4, were initially simulated. The
dimensions and inlet flow rates for each case are shown in Table 3.1. The depth of the main
channels was 30 or 50 μm and the depth of side channel was 10 μm. The total length was
2000 or 4000 μm. The length of the side channel was 400 μm less than Lt; the front 200 μm
was for the entrance section for fully developed flow and the last 200 μm was also for fully
developed outlet flow or a further connection. The inlet flow rate was 0.75 mL/min or 0.075
mL/min. At 0.75 mL/min, the pressure and velocity were very high, as shown in Figure 3.11.
The target flow rate (0.75 mL/min) was obtained using ten parallel devices with the 0.075
mL/min. The cases C1~C4 had the same channel widths of (400 μm for the main channel,
100 μm for the side channels.)
Table 3.1 Dimensions and inlet conditions for constant depth main channels (The width of
the main channel is 400 μm, the depth of side channel is 10 μm, and the initial depth of the
main channel is 30 or 50 μm.)
Cases (g=10 μm)

C1

C2

C3

C4

Width of main channel (W) [μm]

400

400

400

400

Depth of main channel (D) [μm]

30

30

30

50

Length of side channel (Ls) [μm]

1,600

1,600

3,600

1,600

Total length (Lt) [μm]

2,000

2,000

4,000

2,000

Inlet flow rate (Qin) [mL/min]

0.075

0.75

0.075

0.075
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Figure 3.11 shows the pressure and velocity differences as a function of the inlet flow
rate. The independent axis indicates displacement from the inlet to outlet and the Y-axis is
the value of the total pressure or velocity. The X-, Y-, and Z-direction and the reference point
are shown in Figure 3.8. The coordinates X, Y, and X indicate length, width, and depth of the
channel respectively. The pathline was a line along the center of the main channel in the Xdirection which has the maximum pressure and velocity. The center line for cases C1~C3 is
15 μm distance in Z-direction from the reference point because C1~C3 has 30 μm depth of
main channel. The center line for case C4 was 25 μm distance in Z-direction from the
reference point because C4 had 50 μm depth of main channel.
The 30 μm deep channel could not be used for high flow rate (0.75 mL/min) because the
pressure and velocity at near the inlet were very high. Too much pressure leads to a high risk
of rupturing the seal. Moreover, the outlet velocity was also too high in both cases C1 and
C2. High velocity will reduce the time for antigen/antibody binding in the capture area.
Figure 3.12 shows the pressure and velocity difference based on the depth of the main
channel and length of the channel. The maximum pressure changed, not due to the different
lengths but due to the different depths of the channels. The outlet velocity depends on the
depth and length of the channels.
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(a)

(b)
Figure 3.11 Comparison of flow rates: 1.25 [mm3/sec] (C1) vs. 12.5 [mm3/sec] (C2) with
same dimension: (a) pressure difference and (b) velocity difference
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(a)

(b)

Figure 3.12 Comparison by depth and length of the main channel with same inlet flow rate
1.25 mm3/sec (or 0.075 mL/min): (a) pressure difference and (b) velocity difference
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Table 3.2 summarizes the simulation results for the constant depth channel. „Cross Area‟
is the area of the cross-section at each inlet and outlet. „Main Inlet‟ or „Main Outlet‟ means
the inlet or outlet surface of the main channel and „Side Outlet‟ is the outlet surface of the
side channels. Velocity is the mean velocity at each surface. The capital letters „A‟, „Q‟, and
„V‟ indicate cross sectional area, flow rate, and mean velocity respectively. Small letters („o‟,
„s‟, and „in‟) indicate surface of main channel outlet, side channel, and main channel inlet
respectively. For example, As is cross sectional area of side channel, Qin is flow rate of main
channel inlet, and Vo is velocity of main channel outlet.

Table 3.2 Results of the constant depth main channel
Parameter

Model

Constant Depth Main Channel
C1

C2

C3

C4

Main Inlet (Ain)

0.012

0.012

0.012

0.020

Side Outlet (As)
Main Outlet (Ao)
As / Ain

0.032
0.012

0.032
0.012

0.072
0.012

0.032
0.020

2.67

2.67

6.00

1.60

Main Inlet (Qin)
Side Outlet (Qs)
Main Outlet (Qo)
Flow Rate Ratio (%) Qo / Qin

1.250
1.033
0.218

12.504
10.141
2.363

1.250
1.236
0.014

1.250
0.544
0.706

17.43

18.90

1.12

56.51

Main Inlet (Vin)
Side Outlet (Vs)
Main Outlet (Vo)
Vo / Vin

104.20
32.26
18.16

1042.00
316.89
196.95

17.43

18.90

104.20
17.17
1.17
1.12

62.50
16.99
35.32
56.51

1374.26

14014.86

1388.69

512.20

Cross Area (A)
2
[mm ]
Area Ratio
Flow Rate (Q)
3
[mm /s]

Velocity (V)
[mm/s]
Velocity Ratio (%)

Maximum Pressure [Pascal]
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Figure 3.13 shows the streamlines for each case to estimate the location of the target cells
in the channel. The location of the target cells will not be exactly same as the streamlines or
pathlines, but it may follow the trajectory. It is very important to estimate the location of
target cells to maximize the encounter rate. For example, in Figure 3.13 (a), „C1‟, and Figure
3.13 (b), „C2‟, are not much different even through the inlet velocity of the case „C2‟ is ten
times higher than the case „C1‟. It is also similar result of flow rate ratio (%) or velocity ratio
(%) between inlet and outlet for the cases „C1‟ and the case „C2‟ in Table 3.2. The location
of the target cells may not depend on the inlet flow rate. The case „C3‟ in Figure 3.13 (c)
shows that most of the streamlines flow through the outlet (unlike the case „C1‟ or „C2‟)
because 98.88% of the inlet fluid flowed out the side channels. The case „C3‟ indicates that
all of the target cells may encounter the side wall of the main channel. So, the longer channel
may give a better chance of encounter on the side channel. In Figure 3.13 (d), „C4‟, shows
that most of the streamlines flow through the main outlet unlike the other cases (C1~C3)
because the over 56% of the inlet fluid flowed out through the main channel outlet. The case
„C4‟, with a deep main channel, gave less chance of target cells encountering the side walls.
Moreover, even though the inlet flow rate was 0.075 mL/min, the outlet velocity was over 35
mm/s, which is too fast to capture target cells. The case study of the constant depth main
channel, cases C1~C4, gave much valuable information on the flow behavior. The constant
depth channel could not be used for high flow rate cell capture because the outlet velocity
was too high even at the lower inlet flow rate, 0.075 mL/min and the pressure and inlet
velocity were too high at the target flow rate of 0.75 mL/min.
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C1

(a)

C2

(b)
Figure 3.13 Streamlines for each case to predict the location of target cell in the constant depth
main channel: (a) case „C1‟, (b) case „C2‟, (c) case C3, and (d) case C4. The cases „C1‟ and
„C2‟ show the effect of inlet flow rate, the length of the channel effect is shown between the
cases „C1‟ and „C3‟, and the effect of the depth of channel is shown between the cases „C1‟ and
„C4‟. (Continued)
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C3

(c)

C4

(d)
Figure 3.13 Streamlines for each case to predict the location of target cell in the constant
depth main channel: (a) case „C1‟, (b) case „C2‟, (c) case C3, and (d) case C4. The cases
„C1‟ and „C2‟ show the effect of inlet flow rate, the length of the channel effect is shown
between the cases „C1‟ and „C3‟, and the effect of the depth of channel is shown between the
cases „C1‟ and „C4‟. (Continued)
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3.4.2.2

Variable Depth Main Channel

The variable depth main channel configurations (identified as V1~V5 or N1~N3, shown
in Table 3.3), were evaluated to overcome the limitations of the constant depth main channel,
an unacceptable inlet/outet velocity and unreasonable maximum pressure. Two different
types of the main channels were considered: 400 μm width with a 100 μm depth at the
channel inlet, cases V1~V5 shown in Table 3.3, or a 300 μm width with a 150 μm depth at
the channel inlet, for cases N1~N3 shown in Table 3.5. The depth of the side channel was 10
μm for cases of V1~V5 and N1~N3. The total length of the main channel (Lt) was varied
from 2000 to 8000 μm and the length of the variable depth section, (Lv) was 700 μm to 4800
μm. The length of the side channel was 400 μm less than Lt; the front 200 μm was for the
entrance section for fully developed flow and the last 200 μm was also for fully developed
outlet flow or a further connection. The inlet flow rate was 0.75 mL/min (12.5 mm3/sec) for
all cases.

Table 3.3 Dimensions and inlet flow rate of the variable depth main channels. (The width of
the main channel is 400 μm, the depth of side channel is 10 μm, and the initial depth of the
main channel is 100 μm.)
Cases (g=10 μm)

V1

V2

V3

V4

V5

Width of main channel (W) [μm]

400

400

400

400

400

Depth of main channel inlet (D) [μm]

100

100

100

100

100

Depth of main channel outlet (c) [μm]

30

30

30

30

30

700

980

2,800

2,800

2,800

Length of side channel (Ls) [μm]

1,600

1,600

3,600

5,600

7,600

Total length of main channel (Lt) [μm]

2,000

2,000

4,000

6,000

8,000

0.75

0.75

0.75

0.75

0.75

Length of variable depth section (Lv) [μm]

Inlet flow rate (Qin) [mL/min]
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Figure 3.14 shows the pressure and velocity at the center line of the main channel, which
is expected to have the highest pressure and velocity. Five cases were simulated, shown in
Table 3.3: three different lengths of variable depth section (700 μm, 980 μm, and 2800 μm)
and four different total lengths of main channels (2000 μm, 4000 μm, 6000 μm, and 8000 μm)
were considered. The outlet channel depth (or the depth after the variable depth section) of
the main channel was 30 μm, and the initial depth of the main channel was 100 μm for all
cases.
In Figure 3.14 and Figure 3.15 show the effect of the length of the variable depth section
(Lv) and total length (Lt). When the length of variable depth section (Lv) was less than 40
times the length of the initial depth of the variable depth section (Lv is less than 40•h or Lv <
40•h), the maximum pressure was very high (4870 Pascal for V2 and 6313 Pascal for V1) at
the channel inlet section and the velocity was increased until the fluid passes the variable
section along the main channel (cases V1 and V2). For cases V1 and V2, The velocity
increased due to the decreasing cross-sectional area of the variable depth section along the
main channel. The angle of the variable depth section (h/Lv) had to be small enough to let the
fluid smoothly pass through the side channels and to maintain the flow rate in the main
channel. On the other hand, when the length of the variable depth section (Lv) was 40 times
longer than the length of the initial depth of the variable depth section, Lv ≥ 40•h, there was
no velocity overshoot (Cases V3~V5.) Increasing the total length of the main channel (Lt) did
not change the pressure and velocity in the range of the variable depth section (Lv.)
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V5

(a)

V1
V2

V3
V4

V5

(b)
Figure 3.14 (a) Pressure and (b) velocity information based on the variable depth section
length (Lv) and the channel total length (Lt). The cases of the short length of the variable
depth section give higher maximum pressure and velocity overshoot (See the cases of V1 and
V2 in the graphs).
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V1
V2

V3

V4

V5

Figure 3.15 Streamwise velocity through the potential contact line of the target cell; The
cases of the short length of the variable depth section show velocity overshoot (See the cases
of V1 and V2 in the graphs).
However, a longer total length gave a much lower outlet velocity. For example, the outlet
velocity of case V3 was 60.48 mm/s and case V5 was 0.24 mm/s, shown in Table 3.4. One of
the prospective target cell contact regions is near the side channel entrance of the main
channel; the Y location can be 190 μm or -190 μm for 400 μm width of the main channel and
the Z location can be -10 μm from the reference point in Figure 3.8. The streamwise velocity
information at the prospective contact line of the target cell is shown in Figure 3.15.
Velocities for the cases V3~V5 were constant over the range of Lv.
Figure 3.16 shows the pressure contour and velocity vector for the case of V1. There is a
sudden velocity increase near the end of the Lv section which shows the highest velocity
value in Figure 3.14(b) and Figure 3.15. Table 3.4 contains results for the variable depth
main channel design with a 400 μm width main channel (W=400 μm and D=100 μm).
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2 mm

(a)

2 mm

(b)
Figure 3.16 Pressure contour and velocity vector of V1
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Table 3.4 Results of variable depth main channel with 400 μm width of the main channel
Parameter

Variable Depth Main Channel

Model
V1

Cross Area (A)
[mm2]
Area Ratio
Flow Rate (Q)
[mm3/s]

Velocity Ratio (%)

V3

V4

V5

Main Inlet (Ain)

0.040

0.040

0.040

0.040

0.040

Side Outlet (As)

0.032

0.032

0.072

0.112

0.152

Main Outlet (Ao)

0.012

0.012

0.012

0.012

0.012

0.30

0.30

0.30

0.30

0.30

Main Inlet (Qin)

12.50

12.50

12.50

12.50

12.50

Side Outlet (Qs)

9.740

8.870

11.774

12.454

12.497

Main Outlet (Qo)

2.760

3.630

0.726

0.046

0.0030

22.08

29.04

5.81

0.37

0.02

Main Inlet (Qin)

312.50

312.50

312.50

312.50

312.50

Side Outlet (Qs)

304.38

277.20

163.53

111.20

82.22

Main Outlet (Qo)

229.97

302.48

60.48

3.81

0.24

73.59

96.79

19.35

1.22

0.08

6313.4

4870.1

3590.9

3605.8

3581.7

Ao / Ain

Flow Rate Ratio (%) Qo / Qin
Velocity
[mm/s]

V2

Vo / Vin

Maximum Pressure [Pascal]

Based on the velocity, pressure, and streamline information, the short variable depth
channel, such as V1 and V2 in Table 3.3 and Table 3.4 were not suitable. The Lv needs to be
at least 40•h (2800 μm with h = 70 μm, h=D-c in Table 3.3) to avoid the sudden velocity
increase. Reducing the cross-sectional area or reducing the depth of the main channel in the
variable depth section (Lv) causes a reduction in the volume per unit length in the main
channel. The volume reduction rate must match the flow rate of the side channels to maintain
the same velocity in the main channel. Therefore, the slope or angle (h/Lv) needs to be small
enough. Otherwise, reducing the cross-sectional area in the main channel will increase the
velocity due to conservation of mass or the continuity equation for an incompressible fluid.
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(a)

(b)
Figure 3.17 Streamlines of (a) V2 and (b) V3, and pathline of (c) V4 (continued)
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(c)
Figure 3.17 Streamlines of (a) V2 and (b) V3, and pathline of (c) V4 (continued)
The maximum pressure was not significantly affected by the total length (Lt) or the slope
(h/Lv) for the cases of V3, V4, and V5. However, the outlet flow rate and the outlet velocity
of the main channel depended strongly on the total length (Lt) because the length of the side
channel (Ls) increased as the total length of the main channel (Lt) increased (Ls was 400 μm
less than the Lt.) In the cases V3 and V4 in Table 3.3, the outlet velocity of the main channel
was higher than the target velocity, 2mm/s. However, it can be used for CTC capture
application by adding a second side channel which has the same geometry as the constant
depth main channel. The maximum pressure can still be an issue for maintaining the seals;
the seal strength for this low aspect ratio may not be as strong as the seal for high aspect ratio
structures due to the minimum temperatures and pressure conditions necessary during
thermal bonding. Therefore, the depth of the bonding layer for the low aspect ratio case could
not be more than that of the high aspect ratio structures to achieve minimum deformation.
The inlet velocity was very high to achieve the required flow rate of 0.75 mL/min.
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To reduce the inlet velocity, maximum pressure, and deformation the inlet depth of the
main channel was modified from 100 μm to 150 μm (from h=70 to h=120, h=D-c) and the
width of the main channel was reduced from 400 μm to 300 μm (from W=400 to w=300).
Since the cross-sectional area of the main channel entrance was increased, the inlet velocity
and maximum pressure for the 0.75 mL/min flow rate were decreased. The Table 3.5 shows
the dimensions for each case of modified new variable depth channel. The length of the side
channel was 400 μm less than the total length of the main channel. The narrower main
channel should have fewer deformation problems during the thermal bonding process. Three
different lengths of the variable depth (N1, N2, and N3) were simulated to obtain better
performance.

Table 3.5 Dimensions and inlet flow rate of the modified variable depth main channels. (The
width of the main channel (W) is 300 μm, the depth of side channel (g) is 10 μm, and the
initial depth of the main channel (D) is 150 μm)
Cases (g=10 μm)

N1

N2

N3

Width of main channel (W) [μm]

300

300

300

Depth of main channel inlet (D) [μm]

150

150

150

Depth of main channel outlet (c) [μm]

30

30

30

Length of variable depth section (Lv) [μm]

3,600

4,200

4,800

Length of side channel (Ls) [μm]

4,600

4,600

5,600

Total length of main channel (Lt) [μm]

5,000

5,000

6,000

0.75

0.75

0.75

Inlet flow rate (Qin) [mL/min]
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N1
N2

N3

(a)

N1
N2

N3

(b)
Figure 3.18 Pressure and velocity information along the center line in the main channel for
the modified new variable depth channel (w=300 and h=120)
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N1
N2
N3

Figure 3.19 Streamwise velocity information on the prospective target cell contact line for
w=300 and h=120
Figure 3.18 shows that the pressure and velocity for the modified new variable channel cases
(N1~N3) were reduced. Moreover, the streamwise velocity information along the prospective
target cell contact line or region is shown in Figure 3.19. In the case of N3 in Figure 3.19,
there is no velocity increase.
Based on the maximum pressure and velocity data, the case of N3 in the modified new
variable depth main channel cases in Table 3.6 is suitable for a high flow rate design to
capture CTCs. However, the outlet velocity is higher than the desired velocity for the
maximum recovery rate. The detailed information about the flow rates and velocities at each
inlet and the outlets are shown in Table 3.6.
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Table 3.6 Results of cases N1~N3 (modified variable depth main channel with 300 μm width)
Parameter

New Variable Depth Main Channel

Model

N1
Cross Area (A)
[mm2]

Flow Rate (Q)
[mm3/s]
Flow Rate Ratio (%)
Velocity
[mm/s]
Velocity Ratio (%)

N3

Main Inlet (Ain)

0.045

0.045

0.045

Side Outlet (As)

0.092

0.092

0.112

Main Outlet (Ao)

0.009

0.009

0.009

0.20

0.20

0.20

Main Inlet (Qin)

12.50

12.50

12.50

Side Outlet (Qs)

12.22

11.95

12.29

Main Outlet (Qo)

0.279

0.548

0.209

2.23

4.38

1.67

Main Inlet (Qin)

277.78

277.78

277.78

Side Outlet (Qs)

132.84

129.92

109.74

Main Outlet (Qo)

30.99

60.84

23.22

Vo / Vin

11.16

21.90

8.36

2765.02

2563.63

2424.93

Ao / Ain

Area Ratio

N2

Qo / Qin

Maximum Pressure [Pascal]
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Figure 3.20 Pathlines colored by time for case of N3

Pathlines colored by time for case of N3 are shown in Figure 3.20. Most pathlines flow
out through the side channels. The travel time for the target cell was extremely short (less
than 0.02 second) from the inlet to the side outlet. So, there may not be enough time for
antigen/antibody reactions. However, when the target cells contacted the side channel
entrance, the target cells will stop at the collision point and give sufficient time for
antigen/antibody reaction without rebounding due to the low elasticity of the cell.
The lateral velocity was investigated at the moment of target cell collision or exclusion.
The collision path line or prospective exclusion path line were the initial contact lines of
target cell at the side channel entrance. It was determined 10 μm away from the side channel
in the main channel and 10 μm below the top surface of the main channel. Figure 3.21 shows
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the collision path line. Two phase flow simulations or cell capture experiments are needed to
estimate the true location of the target cell collision with the wall. The axial and lateral
velocities are shown in Figure 3.22 for cases V3~V5 and case N3 for comparison.

Reference Point

X
Y

Side Channel

Collision Path
Line

Z

Main Channel
Target Cell

Figure 3.21 Collision path line (X=10 µm and Y= 10 µm) and reference point in a cross
sectional view of main and side channels

3.4.2.3

Results of High Flow Rate Device Version One

The „N3‟ configuration in Table 3.5 was selected because it gave a lower maximum
pressure, inlet velocity, and potentially lower deformation during sealing process. It could
reduce the 98.7% of flow rate and 81.6% of mean velocity which is shown in Table 3.6.
However, the outlet flow rate is 0.2 mm3/s and mean outlet velocity is 23.33 m/s. To reduce
the flow rate and the mean velocity at the main outlet region, the end of the main channel
needed to be connected to secondary channels, such as a longer constant depth channel
(C1~C4.) The effect of the longer channels (Lt and Ls) is shown in Table 3.2 (C1 and C3)
and Table 3.4 (V3~V5). The outlet velocities from C1 to C3 in Table 3.2 or from V3 to V4
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or V5 in Table 3.4 are exponentially reduced. Additionally, the depth of the second main
channel can be 30 μm to avoid potential target cell loss. By manipulating the flow rate at
each outlet, including the side and main channel outlets, the flow rate of each outlet and
velocity vector in each region could be controlled and cell loss can be avoided because the
lateral force and centrifugal force of the target cells can be controlled.

Cases of V3~V5
Axial Velocities

Lateral Velocities

(a)

Case of N3
Lateral Velocity
Axial Velocity

(b)
Figure 3.22 Axial and lateral velocities on the exclusion path line (X=10 µm and Y= 10 µm)
for (a) the case V3~V5 and (b) the case N3
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3.4.3.

High Flow Rate Device Version Two (HFRD2)

The second version of the high flow rate device (HFRD2) was designed and simulated
because the first version (HFRD1) had target cell loss issues after demonstration. The 10 µm
deep side channels in the HFRD1s allowed target cell loss through the side channels due to
deformation of the target cells. The cross-sectional area for cases N1~N3 of the main channel
inlet also limited the maximum flow rate. The depth of the side channels was reduced to 5
µm for the HFRD2 and the cross-sectional area of the main channel inlet was increased.
The design of the HFRD2 focused on overcoming the target cell loss, minimizing the
mean axial velocity in the second channel, and reducing the lateral velocity along the
exclusion path. The simulation conditions are shown in Table 3.7.
Table 3.7 Simulation conditions for HFRD2
SIMULATION CONDITIONS
Goal

High Flow Rate Microdevice to Capture Rare Target Cells

Tool

Gambit v2.4, Fluent v6.3, Tecplot 2008

Design Target

Constraints

Assumption
Boundary conditions
Material





Inlet flow rate: 0.75 mL/min
Mean outlet velocity of main channel: < 2 mm/s
Minimum lateral velocity at side channel: No target cell loss






Depth of main channel inlet: 130 μm to minimize inlet velocity
Depth of second section: ~ 30 μm for the maximum recovery rate
Depth of side channel: 5 μm to avoid target cell loss
Width of side channel: ~ 100 μm for minimum deformation and
fabrication possibility

Target cells will follow velocity vector or stream/path line
Velocity inlet, pressure outlet (atmosphere pressure)
Water
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The HFRD2s used two sections to control the flow rate and velocity in each section by
manipulating the outlet flow rates. The first section had the variable depth main channel –
with the depth decreasing from 130 to 30 µm. The width of the HFRD2 was reduced to 1 mm
to reduce the inlet velocity and decrease the maximum pressure and collision velocity of the
target cells. The 30 µm depth in the second section was to maximize the recovery rate. A
schematic of the HFRD2 is shown in Figure 3.23.

2 mm

Figure 3.23 Schematic drawing of the HFRD2
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Lt
Y
X
(a)

Lv

L1

L2

Z
X
(b)

S
g

W

c

Z

h

Y
(c)
Lt: Total length of main channel
L1: Length of 130 µm depth main channel
Lv: Length of variable depth section
L2: Length of 30 µm depth main channel

W: Width of main channel (W=1 mm)
S: Width of side channel (S= 100 µm)
c: Depth of main channel at L2 (c=30 µm)
h: Initial depth of the variable depth section

g: Depth of side channel (g= 5 µm)

(h = 100 µm)

Figure 3.24 Dimensions of the first section for the HFRD2: (a) top view of the channels, (b)
side view of channels, and (c) front view of the channels

Table 3.8 Cases of the first section on HFRD2 (g= 5µm)
Cases

L1 [mm]

Lv [mm]

L2 [mm]

Lt [mm]

G1
G2

10
5

6
6

3
8

23
23

G3
G4

5
10

9
10

12
0

30
24

83

Four cases were simulated for the first section of the HFRD2. The schematic and the
dimensions for each case are shown in Figure 3.24 and Table 3.8 respectively. The axial
mean velocities versus the distance from the inlet to outlet in the first section are shown in
Figure 3.25. The inlet velocity was 96.2 mm/s to obtain the target flow rate of 7.5 mL/min.
Cases G1 and G2 show an increasing velocity at the end of Lv region because the decreasing
ratio of main channel depth is too large compare to flow rate capacity of the side channel at
that region. Since the axial velocity should be minimized for the maximum duration time in
the second section, case G3 can be an option for the first section dimensions. However, case
G3 may produce a backflow from the end region of the first section reservoir to the main
channel or to the second section due to too low a flow rate with suction at the main outlet to
control the flow rate. It is also possible to show no flow at the end of second section if there
is no flow rate control at the main outlet or if there is reverse pressure gradient between the
reservoir and the main channel in the second section. Case G4 has a higher axial mean
velocity than case G3 at the end region, but the mean axial velocity will be reduced in the
second section. The total length (L1+Lv+L2) is shorter than case G3 and the slope of the Lv
region is lower than case G3, so case G4 was chosen for the first section design. Simulation
was individually performed for the first section and second section due to a hardware
limitation.
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Axial Mean Velocity [mm/s]

100

96.17
G1
G2
G3
G4

90
80
71.05
70
60
50
44.17
40
30
20

16.99
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7.35
1.11

0
1

3

5

7

9
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15
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19
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23

25

27

29

Location [mm]

Figure 3.25 Axial mean velocities of the first section cases on HFRD2
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The second section was also simulated to identify the best dimension. The second section
had a constant depth main channel (c= 30 µm) and different length channels for each case.
The schematic of the second section is shown in Figure 3.26 and dimensions for each case
are shown in Table 3.9. Multiple inlet velocities for cases were simulated to check the effect.
The results of the simulations of the second channel are shown in Figure 3.27. The slopes of
the axial velocities were not dependent on the length (Ls) but rely on the inlet velocities.

Ls
Y
X
(a)
Z
X
(b)

S

W
c

g
(c)
Ls: Total length of side channel
c: Depth of main channel (c=30 µm)
g: Depth of side channel (g= 5 µm)

W: Width of main channel (W=1 mm)
S: Width of side channel (S= 100 µm)

Figure 3.26 Dimensions of the second section for HFRD2: (a) top view of the channels, (b)
side view of channels, and (c) front view of the channels
Table 3.9 Cases of the second section on HFRD2 (g= 5µm)
Cases

Ls [mm]

S1
S2
S3
S4

12.5
18
25
33
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50

Axial Mean Velocity [mm/s]

45

S1 (V=10 mm/s)
S1 (V=20 mm/s)
S2 (V=10 mm/s)
S2 (V=20 mm/s)
S3 (V=20 mm/s)
S4 (V=45 mm/s)

45.00

40
35
30
25
20

20.00

15
10

10.00

5
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
Location [mm]

Figure 3.27 Axial mean velocities of the second section cases for the HFRD2 with multiple
inlet velocities
Based on the multiple simulations for the first and second sections, cases G4 and S4 were chosen
for prototype dimensions. The results of the total channel (first section + second section)
simulation is shown in Figure 3.28. The axial mean velocity of the case HFRD2 which is
combined with case G4 and S4 is shown in Figure 3.28. It has less than 1 mm/s velocity after 34
mm away from the inlet with the 96 mm/s inlet velocity which gives the target inlet flow rate, 7.5
mL/min. However, the simulation was based on water only and reservoir was not considered due
to limits on the mesh element number. Moreover, it was assumed to be a Newtonian fluid. Axial
accumulation of erythrocytes may help to keep the target cells in the main channel because the
erythrocytes may occupy the highest velocity zone in the channel (near the side channel and core
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of the main channel) but this phenomenon was not considered [11-13]. Multiphase simulation
with whole blood components may give more information.

Axial Mean Velocity [mm/s]

100

96.47

90
80
70
60
50
40
30
24.59
20
10
3.66
0
1

3

5

7

9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55
Location [mm]

Figure 3.28 Axial mean velocities of the total channel (first section G4 + second section S4) for
the HFRD2
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3.4.4.

High Flow Rate Device Version Three (HFRD3)

A schematic of the third high flow rate device (HFRD3) is shown in Figure 3.29. HFRD3
has two sections to control flow rate and velocity in each section by manipulating the outlet
flow rates to match the simulation result if necessary. The first section has a variable depth
main channel - the depth decreases from 130 to 30 μm which is purple channel in Figure 3.29.
The selection of the 130 μm depth and 5 mm width for the main channel were to reduce the
highest axial velocity, lateral velocity, and the pressure by reducing the inlet velocity. The
simulation conditions are the same as case HFRD2 and are shown in Table 3.7.

Figure 3.29 Schematic drawing of the high flow rate device version three (HFRD3)
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The enlarged width of the main channel in the Lv, which has decreasing depth, will help
to reduce the length of Lv without increasing the velocity. The reduction of the crosssectional area in Lv by decreasing the depth was recovered by increasing width. The wider
main channel in the second section with a 30 μm deep main channel will also help to
decrease the velocity to maximize cell capture. The detailed dimensions of the first section
and each case are shown in Figure 3.30 and Table 3.10.

Figure 3.30 Dimensions of the first section for the HFRD3

Table 3.10 Cases of the first section on HFRD3 (g= 5µm)
Cases

L1

Lv

L2

Wo

P1

20

6

3

5

P2

10

10

0

10

P3

20

10

0

10

P4

20

10

4

10
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The axial mean velocities as a function of location in the first section are shown in Figure
3.31.The inlet velocity was 19.24 mm/s, which is 20 % of cases HFRD2 (V= 96.2 mm/s) for
7.5 mL/min. The outlet velocity of case P2 was higher than the initial velocity due to the too
large a reduction in the main channel depth. Based on the outlet mean axial velocity results,
case P2 is not a good option to minimize the inlet velocity at the second section entrance.
The other cases (P1, P3, and P4) were suitable options for the first section channel based on

Axial Mean Velocity [mm/s]

the mean axial velocity results.

25

P1
P2
P3
P4

24.31
21.83

20

19.24
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18.35
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12.84
11.26
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8.11
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1
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Figure 3.31 Axial mean velocities of the first section cases for HFRD3
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It is very important to investigate the collision velocity or prospective exclusion velocity
(the lateral velocity of the target cells at the moment of contact or exclusions) to avoid target
cell loss. The Figure 3.32 shows the cross-sectional view of the side and main channel. The
path of the lateral velocity (collision velocity, or exclusion velocity) is shown in Figure 3.32.
The circle in the main channel indicates the target cell. The exclusion path line for the lateral
velocity was the x-direction line which was 5 μm from the side channel and 5 μm from the
top surface. The path line: (X, Y, Z) = (X, 5 μm, 5 μm) from the reference point in Figure
3.32. The lateral velocities for cases P1~P4 are shown in Figure 3.33. Cases P2 and P3 had
lower lateral velocities compared the other cases. Therefore, P3 is a good option for the first
section design since P2 is not acceptable due to the high axial mean velocity at the end.

Reference Point

X
Y

Side Channel
Collision Path Line

Z

Main Channel
Target Cell

Figure 3.32 Collision path line (X = 5 µm and Y = 5 µm) and reference point in a cross
sectional view of main and side channels
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P1

P4

P2
P3

Figure 3.33 Lateral velocities on the collision path for each case of HFRD3
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The second section was designed as 30 μm depth of constant main channel with 5 μm
depth of side channel which is similar with S4 in Figure 3.26 except the width of main
channel. The width of the main channel of the second section for the HFRD3 was 10 mm.
The schematic and dimensions are showing in Figure 3.34. The length of the side channel
was determined as a maximum length. It was limited to 33 mm due to the size restrictions of
the brass mold insert used. The mean axial velocity of the second section is showing in
Figure 3.35. The mean axial velocity at the end was less than 2 mm/s which is lower than the
target velocity. A longer second section would give a lower velocity with a larger mold
insert.

Ls
Y
X
(a)
Z
X
(b)

S

W
c

g
(c)

Ls: Total length of side channel (Ls=33 mm) W: Width of main channel (W=10 mm)
c: Depth of main channel (c=30 µm)

S: Width of side channel (S= 100 µm)

g: Depth of side channel (g= 5 µm)
Figure 3.34 Dimensions of the second section for HFRD3: (a) top view of the channels, (b)
side view of channels, and (c) front view of the channels
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Figure 3.35 Axial mean velocity of the second section of the HFRD3
The design of HFRD3 was completed based on the axial velocity and the lateral velocity.
The first section was chosen as case P3 and the length of the second section was 33 mm.
Since the minimum collision velocity of the target cell on the 5 μm depth of side channel to
avoid the target cell loss is still unknown, designing minimum lateral velocity will give
maximum flow rate device. The complete device could not be simulated because the required
number of mesh elements was not acceptable for a conventional computer. High performance
computing may solve the hardware limitations and time issues for the simulation of the
complete device. Subsequent target cell capture experiments will verify the simulation results.
Figure 3.36 shows the mean axial velocity for the total device (the first section and the
second section) and Figure 3.36 shows the lateral velocities of the first and second section
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channel. The pathlines of the first section and second section are shown in Figure 3.38 and
Figure 3.39.

Axial Mean Velocities [mm/s]

20
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The First Section
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The Second Section
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67

Location [mm]
Figure 3.36 Axial Velocities of the first and second section channel for HFRD3

Figure 3.37 Lateral velocities of the first and second section channel for HFRD3
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Figure 3.38 Pathlines of the first section for HFRD3

Figure 3.39 Pathlines of the second section for HFRD3
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3.5 Analytical Solution of Side Velocity
The average side velocity can be briefly determined by the design target and constraints
with channel geometry. Since the lateral velocity or collision/contact velocity should not
exceed the exclusion velocity of the target cell to avoid target cell loss, the side velocity is
important. Table 3.11 shows the design goal and constraint: target flow rate, target outlet
velocity, depth of main channel at the main outlet, depth of side channel. The simplified
channel geometry is shown in Figure 3.40. Assume that two side channels are connected to
the main channel having one inlet, two side outlets, and one main outlet. The continuity
equation is
Q=A•V

(1)

The Q is flow rate, A is cross sectional area, and V is mean velocity. The conservation of
mass flow rate for an incompressible fluid yields
Qin=2Qs+Qo

(2)

The Qin is the inlet flow rate, the Qs is the outlet flow rate at side channel, and the Qo is the
outlet flow rate of the main channel. Based on the Table 3.11 and the two equations,
continuity and conservation of mass flow rate for an incompressible fluid, the side velocity
(Vs) is a function of the main channel outlet width (Wo) and the length of the side channel
(Ls):

(3)

Table 3.11 Constraints of high flow rate device with constant depth main channel
Inlet Flow Rate
(Qin)

Outlet Velocity of
the Main Channel

Depth of Main Channel
at the Main Outlet

Depth of Side Channel

0.75 mL/min

< 2 mm/s

30 μm

5 μm
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Figure 3.40 Simplified design of HFRD; Qin, Qs, and Qo indicate main inlet flow rate, side
outlet flow rate, and main outlet flow rate respectively. (Ls: length of side channel, Wo:
width of main outlet)

From Equation (3), a plot of the mean side velocities (Vs) is shown in Figure 3.41 based
on the main channel outlet width (Wo) and the side channel length (Ls). Each line in Figure
3.41 indicates a different length of the side channel. For example, Vs (Ls=70 mm) is the case
of a 70 mm of the side channel length. Applying this to HFRD3 with a 10 mm outlet width
and 60 mm length of side channel, the average side velocity can be approximated as 20 mm/s.
This also indicates the the maximum lateral velocity for that case may be higher than 20
mm/s. To get a lower maximum lateral velocity (Vs), a longer side channel or wider exit is
required. It can be useful for estimating the ideal side velocity.
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Figure 3.41 Graph of the side velocity as a function of main channel outlet and side channel
length
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3.6 Conclusions
A new concept for a target cell capture device using antigen/antibody binding was
introduced and realized. Side channels were combined with a main channel. The depth of the
side channels was determined as 5 µm based on the demonstration and simulation results.
Depth of the main channel in the second section was 30 µm for the maximal encounter rate.
A drilling guide was introduced for the inlet reservoir to minimize target cell loss due to
misalignment. From the multiple simulation results and demonstration, inlet velocities were
reduced by enlarging the inlet cross-sectional area. Lateral velocities, or the collision velocity,
near the side channel were minimized to avoid target cell loss. Mean axial velocities in the
second section were minimized for maximal target cell recovery rate. An analytical solution
of the side velocity was established. However, the simulation was based on the Newtonian
fluid and assumed the target cells will follow the path line. Moreover, blood rheology was
not considered for this simulation. Experiments with whole blood are needed to verify the
simulation results.
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CHAPTER 4: EXPERIMENTS

4.1 Introduction
Target cell capture experiments were grouped in three steps. The first step was device
preparation, including device design and fabrication, surface functionalization and antibody
immobilization, sealing, and capillary connection.

The second was sample preparation

including obtaining single or small numbers of CTC. The third was CTC capture and
identification including target cell capture from human blood and investigation of the capture
location. Detailed processes and new protocols are introduced in this chapter. Device design
was finalized from simulation results, Chapter 3. The device was fabricated on polymethyl
methacrylate (PMMA) using hot embossing with a micro milled brass mold insert because it
is a relatively fast, simple, and inexpensive process compare to the LIGA process. Sealing of
the high flow rate device was a challenge due to its very low aspect ratio and large thickness
variation of the PMMA device. A new sealing protocol was established that overcame the
sealing issues. Surface functionalization and antibody immobilization were accomplished and
verified using a second antibody. New sample preparation methods were introduced and
applied for rare target cell capture experiments. The results for CTC capture with the capture
location in the device are presented.

4.2 Fabrication of a Polymer Micro Chip
Poly(methyl methacrylate), PMMA, was used for the cell capture device because the
PMMA is an inexpensive and biocompatible thermoplastic material. Therefore, it is
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applicable for disposable devices and clinical use. Moreover, fabrication of the PMMA
device is a relatively fast and easy process compared to silicon or other hard material
fabrication. PMMA or polymer devices can be fabricated using LIGA (or LIGA-like), micro
milled mold inserts, polymer direct milling, or laser ablation. Polymer direct milling and
laser fabrication processes are not suitable for mass production of cell capture devices due to
the relatively slow process and resulting rough side walls. The LIGA (or LIGA-like) process
can give precise dimensional control of the device, but it is a relatively complicated, multi
step process, to achieve a mold insert. Unlike other processes, micro milling technology is
much simpler and faster and it is also suitable for a multi height or level mold insert. Once a
mold insert is fabricated, PMMA devices can be continuously fabricated using hot embossing
or injection molding. Therefore, hot embossing or injection molding with a micro milled
mold insert was very acceptable method for mass production and for the fabrication of the
cell capture device. PC (Polycarbonate) and Cyclic Olefin Copolymer (COC) can also be
used for the cell capture device, but both are more difficult to functionalize.
4.2.1

AutoCAD Drawing and PMMA Device Fabrication

AutoCAD v2008 (AutoDesk, Inc., San Rafael, CA, USA) was used for the mold insert
design. The height of each layer was used as the name for each layer, for easy identification.
Therefore, the layer names in AutoCAD indicate different height structures on the mold
insert. Since brass, an alloy of copper and zinc, was used for micro milling the mold insert,
the aspect ratio cannot be more than five. Multiple designs or duplicated structures in a mold
insert were used to reduce the number of mold inserts or the hot embossing (or injection
molding) processes. Each design or structure on a mold insert was isolated using tall (500 μm)
and wide (700 μm) rectangular structures, shown in Figure 4.1. The surrounding outline
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structures also aided in filling of the polymer during hot embossing and enabled clean cutting
of each device from the substrate after hot embossing. The rectangular outline structures
should be separated to extract trapped air in the outline during hot embossing. The trapped air
prevents the complete filling of the mold with polymer. Free or empty area around the each
device pattern was occupied by dummy structures. The dummy structures will help to
achieve a straight long channel during hot embossing and also reduce trapping of air during
thermal bonding.
The polyline option in AutoCAD was used to test the connectivity of all of the lines and
to be compatible with the operating software for the micro-milling machine. Based on the
AutoCAD drawing, the brass mold insert was fabricated using a micro-milling machine
(MMP, KERN Micro- und Feinwerktechnik GmbH & Co. KG, Eschenlohe, Germany). For
micro-milling, a 1 mm diameter bit rotating at 30000 rpm and a 350 mm/min feed rate was
used. For finishing, a 200 μm diameter diamond tool was used while turning at 40000 rpm
with a feed rate of 150 mm/min.
For the mold insert labeling, “Name-Dimension-Date” was used. For example TP020100-0107, „TP‟ means Taehyun Park`s mold insert, the „020100‟ indicates a depth and
width of channel (20 μm depth and 100 μm width), and the „0107‟ tell the fabrication date of
the mold insert (Jan/2007).
From the brass mold insert, the PMMA cell capture devices were hot embossed using a
Jenoptik HEX 02 (Jena, Germany) system at the Center for Advanced Microstructures and
Devices (CAMD) at LSU. The PMMA was MC grade Plexiglas (Champion Industrial
Plastics, Baton Rouge, LA, USA) and the thickness was 1/16 inch. A schematic of a hot
embossed PMMA device is shown in Figure 4.1 (b).
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Hot embossed polymer devices were cut along a cutting guide groove, which was defined
by the outline structures on the mold insert, by table saw (Microlux, Japan.) The cutting
guide grooves, 700 μm wide and 500 μm deep, gave clean cut edges on the device and
minimized the variation of contact area between the actual device dimensions and the initial
design which was used for contact area calculations.

Dummy structures

Reservoir

Cutting guide
groove
Outline structure
(a)

(b)

Figure 4.1 Illustration of (a) brass mold insert and (b) hot embossed PMMA device

4.2.2

Connection Issues for the Microfluidic Chip

Connections from the macro capillary tubes to the micro channels are very important for
rare cell capture experiments because cells can be trapped or lost through improper
connection or non-smooth geometric features. The device and connector should minimize the
recirculation volume for minimum cell trapping or cell loss during target cell transportation.
Moreover, the working solution should flow smoothly from the capillary tube to the micro
channel through a reservoir area in the microchip. However, there is dead volume along the
flow path and the recirculation usually occurs in the dead volumes and causes cell loss or
trapping. Elimination of the dead volumes would be the best solution but it is still a challenge
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since it is a product of the size change, from macro to micro, and geometric profile
differences, such as from circular to rectangular. Inlet ports to connect with the capillary
tubes were drilled. The size of the drill bit was similar with the outer diameter of the capillary
to reduce the dead volume and for smooth flow of the working solution. Otherwise, the gap
between the outer surface of the capillary and inner surface of the drilled hole will create
dead volume and recirculation.
The drilled hole should be clean and should not have burrs to minimize cell trapping by
the rough surface or burrs on the edge of the drilled holes. The maximum rotation speed
(5000 rpm) on the drilling machine (Microlux, Japan) was used to minimize burr formation.
The location of the drill center was also important because the mismatch between the center
of the reservoir and core of the capillary will create significant dead volume and in the worst
case may block the sample flow. Figure 4.2 shows the mismatch and burrs between the
centers and the improved design to reduce the mismatch. Drilling positions for the Figure 4.2
(a) and (b) were determined by naked eye without a drill guide hole which was explained in
Section 3.3.2. To minimize cell trapping at the reservoir due to the sudden contraction or at
the edge of the drilled hole due to burrs, the inlet reservoir was deeper than the channel
entrance area. The reservoir design is showing in Figure 4.2 (c). Tall burrs on the edge of the
drilled hole will block the target cell if the reservoir is not deep enough.
The cleaving of the capillary tube end was also important, especially for fused silica
capillaries. Improper end cleaving of the capillary will block the sample flow or trap the
target cells. Cells tend to stick to the unclean end on the capillary. Examples of the capillary
end cleaving are shown in Figure 4.3.
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Polymer Capillary
Silica Fused
Capillary

Reservoir

Drilled hole
with big burrs

Reservoir
(a)

(b)

Drilling guide
structure

Reservoir

Reservoir
Channel

Drilled hole

(c)

(d)

Figure 4.2 Cross-sectional view of the reservoir showing the mismatched centers and
improved design; (a) The mismatch between the silica fused capillary center and the
reservoir center was over 200 μm with huge burrs around the drilled hole which was much
larger than the inserted capillary. (b) The mismatch between the polymer capillary center and
the reservoir center was approximately 160 μm, and the gap between the outside of the
capillary and the inner surface of the drilled hole are relatively small. The burrs on the edge
of the hole were reduced with high rpm (>3000 rpm.) (c) Red cylindrical structure at the
reservoir center on the mold insert indicates the drill guide structure. (d) Center drilled hole
using the improved design has less than 10 μm mismatch.
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(a)
(b)
Figure 4.3 Example of capillary end cleaving: (a) improper end cleaving and (b) fine end
cleaving

Once the device was cut and drilled for capillary connection, a cleaning process was
carefully done to eliminate residual particles in the channel or burrs on the reservoir which
can block the flow of cells. Cleaning was done using ultrasound (Branson, Danbury, CT,
USA) with 90% demonized water (DI water) mixed with 10% Isopropyl alcohol (IPA).
During the ultrasonication, the temperature of the solution should not be warmed to avoid
deformation of melting of the PMMA device. Sonication with isopropyl alcohol mixed with
DI water can remove sharp burrs and particles on the device. However, some of the particles
in the channel may not be removed. For complete removal of these particles, high pressure
nitrogen gas (over 60 psi) was used. After sonication and nitrogen gas cleaning, the polymer
device was rinsed with DI water. After all of the cleaning steps, the channels were carefully
examined under a microscope and stored in a 70 ~ 85 °C oven (VWR 1620, West Chester,
PA, USA) for overnight for dehydration and annealing.
4.3 Polymer Modification and Functionalization
Antibody immobilization on polymer surfaces is one of the main processes for cell
capture. Pristine PMMA (-COOCH3) can be modified to a carboxyl group (-COOH)
modified PMMA surface using UV modification. The carboxylated group can be amine
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functionalized

(-NH2)

by

adding

ethylenediamine

with

EDC

(1-Ethyl-3-(3-

dimethylaminopropyl)-Carbodiimide) [1-4]. Finally, the amine functionalized surface can be
replaced by an antibody immobilized surface using EDC coupling with antibody (AB) [5, 6].
The illustration in Figure 4.4 shows the chemical structure changes on the polymer surface
during the modification and functionalization process.
Antibody (AB)
EDC

Ethylendiamine
EDC

PMMA

PMMA

PMMA

CO-NH…NH-AB

CO-NH…NH-AB

CO-NH…NH-AB

CO-NH…NH-AB

CO-NH…NH2

CO-NH…NH2

CO-NH…NH2

CO-NH…NH2

COOH

COOH

COOH

COOH

COOCH3

COOCH3

COOCH3

COOCH3

UV

PMMA

Figure 4.4 PMMA modification and functionalization process [1]
4.3.1

UV Modification of the Polymer Surfaces

Pristine PMMA was modified using an ultraviolet (UV) exposure station (ABM, Inc.,
San Jose, CA). The wave length of the UV station was 254 nm and its UV intensity was
approximately 15 mW/cm2.
Surface modification using UV exposure and isopropyl alcohol (IPA) rinsing process
changes the properties of the PMMA surface from hydrophobic to hydrophilic. Hot
embossed PMMA showed approximately a 92 degree water contact angle; after UV exposure
(5 ~ 20 min) the average of water contact angle was between 90 ~ 100. Further IPA rinsing
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dropped the average water contact angle to 70 ~ 75. The water contact angle of PMMA
shows a different result from previous studies which used pristine PMMA [1-3]. The PMMA
was hot embossed PMMA and roughness was changed. MC grade PMMA from Plexiglas
(Altuglas Int`l., Philadelphia, PA) and Cyro Acrylite FF grade PMMA (Evonik Cyro,
Parsippany, NJ) were used. The water contact angle was measured before UV modification,
after UV modification, and after IPA rinse. This is because of surface roughness changes
from the hot embossing using a micro milled brass mold insert, or different type/grade of
PMMA. However, the water contact angle after the IPA rinse was not much different from
the previous study using pristine PMMA [1-3]. Figure 4.5 shows the change of the water
contact angle before and after the IPA rinse as a function of the UV exposure time. Appendix
B shows the detailed data on the water contact angle experiments.
For a 15 mW/cm2 intensity of the 254 nm wave length UV light, the exposure time was
chosen as 6~8 minutes to avoid surface damage. However, the surface damage depends on
the PMMA type (manufacture, grade, fabrication) and process (hot embossed or pristine
PMMA). For example, the CQ PMMA (Vista Optics, Widnes Cheshire, UK) did not show
the surface damage under the same conditions with other PMMA.

Table 4.1 Protocol of UV Modification for Carboxyl Group (-COOH) Modified PMMA
Steps
1

Processes
Expose the cleaned PMMA under UV light for 8 min.
(Exposure time depends on UV intensity and PMMA type)

2

Wait until the exposed PMMA cool down.

3

IPA rinse and DI water rinse.

4

Nitrogen gas dry.
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Hot Embossed
PMMA

(a)

(b)
Figure 4.5 Water contact angle after UV exposure: (a) before IPA rinse (b) after IPA rinse
(The middle value on the vertical line indicates the average of the water contact angle, and
upper and lower little horizontal bars indicate the maximum and minimum value of water
contact angle at each exposure time.)
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10 minutes

30 minutes

60 minutes

Figure 4.6 Surface damage of the PMMA depends on UV exposure time; UV exposure time
shown under the each pictures.
Figure 4.6 shows the physically damaged PMMA surface based on the different exposure
times under 15mW/cm2 UV. After 10 minutes of UV exposure the PMMA surface was clean
but at 30 minutes of exposure the PMMA surface was a milky color. For a 60 minute
exposure, the PMMA surface was totally damaged. Additionally, the intensity of the UV can
be changed due to the UV lamp condition and the exposure time should be changed based on
the UV intensity. For a 20 mW/cm2 intensity of the 254 nm wave length, a 200 second
exposure time was selected.

4.4 Thermoplastic Fusion Bonding
Sealing of the PMMA device is an important process. The device requires a strong bond
without contamination and with minimal deformation of the geometry. It should be strong
enough to avoid device rupture under high pressures in the channels. Contamination can be
an issue for biological applications. Deformation will also lead to uncertain flow behavior.
There are many bonding techniques for polymer micro devices [7-16]. However,
thermoplastic fusion bonding or thermal bonding is the recommended method for the cell
capture device because it can provide a strong bond without any contamination. The simplest
polymer sealing method is using a glue or adhesive, such as an epoxy or acrylate. However,
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it may cause several problems such as channel clogging by extra glue or solution leaking into
any gaps between the parts and the adhesive layer. Moreover, contamination by the adhesive
or glue layer can be a problem for biological applications. Laminated adhesive film may be
used for polymer sealing [12, 13]. However, it may also have a potential contamination issue
and limited material uses. Solvent bonding is a relatively easy method, but it requires
complete removal of the solvent and is not recommended for functionalized devices [16].
Welding using either laser or ultrasound is a complicated process and requires special tools
and specific geometries at the interface for best results. Therefore, thermal bonding was
selected and tried for all polymer cell capture device sealing.
4.4.1

Glass Transition Temperature of a Polymer

The glass transition temperature (Tg) of a polymer is very important for thermal bonding
because the three basic parameters (temperature, pressure, and time) of thermal bonding are
dependent on the glass transition temperature of the polymer.
Polymers are viscoelastic materials which have elastic and viscous behavior. There are
five regions as a function of temperature for linear amorphous polymers, shown in Figure 4.7.
The first region is the glassy region where brittle behavior is common – this is true for
PMMA at room temperature. In this region the Young`s modulus of the polymer is constant
up to the just below of the glass transition temperature. The second region is the glass
transition region (leathery behavior.) In this region the polymer will be affected even by a
few degrees temperature change.
The glass transition temperature is usually at the part of the maximum rate of turndown
of the modulus or at the temperature where the coefficient of thermal expansion (CTE)
exhibits a discontinuity. In the glass transition region the number of chain atoms in motion
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Tg

Figure 4.7 Illustration of viscoelastic behavior (five regions) for a linear amorphous
polymer. Dashed line is for crystalinity effect and the dotted line is for cross-linking
effect [19].
are 10 ~ 50 (40 for PMMA) while only 1 ~ 4 chain atoms are in motion below the glass
transition temperature [17, 18]. A simple explanation of the glass transition is that the
polymer is between glassy and rubbery states or a sharp drop of Young`s modulus, as shown
in Figure 4.7 [19].
The third region is a rubbery plateau region where an elastomer can be stretched more
than one hundred percent. For semi-crystalline polymers, the polymer behavior will follow
the dashed line after the second region in Figure 4.7. The fourth region is a rubbery flow
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region which shows both rubber elasticity for a short time scale experiments and flow
behavior for long time scale experiments. In this region, there is no cross-linking. The last
region of the linear amorphous polymer as temperature increases is the liquid flow region in
which the polymer flows readily.
The glass transition can be experimentally found by measuring the thermodynamic,
physical, mechanical, or electrical properties with temperature changes. The methods for
measuring glass transition temperature are based on measuring properties, such as the
volume, modulus, or dielectric loss. There are three main theories describing the glass
transition temperature of polymer as a molecular level [20, 21]; free-volume theory, kinetic
theory, and thermodynamic theory. The free-volume theory starts from existing voids in the
bulk states. The voids, vacant or empty space between molecules, are called free volume and
depend on the pressure. A pressure increase causes both the total volume and the free volume
to decrease. The deceasing volume increases Tg. The pressure coefficient of the glass
transition temperature, dTg/dP, for PMMA is 0.02 ~ 0.023 K/atm at Tg = 105°C [22]. The
kinetic theory of glass transition implies that the change of the glass transition temperature is
based on a time frame; the glass transition temperature of a polymer shifts 6 ~ 7 °C per
decade. The thermodynamic theory involves the variation of Tg with the molecular weight
and cross-link density, dilution content, and other variables. The glass transition temperature
is related to the cross-link density, molecular weight, polymerization or copolymerization,
time, crystallinity, chemical structure, tacticity, and pressure.
The polymer properties at or near the glass transition temperature are the main concern
for thermal bonding. At or near Tg or in the glass transition region in Figure 4.7, small
temperature increases cause large decreases in the Young`s modulus of the polymer
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compared to the glassy state [23]. The deceased Young`s modulus increases the deformation
during the thermal bonding process. Therefore, precise temperature control is needed for
minimum deformation during thermal bonding.
The operating pressure during thermal bonding will also affect the deformation. The time
variable for thermal bonding may not effect much more than the other parameters,
temperature and pressure. After an hour of thermal bonding operation, the thermal bonding
result (sealing force and deformation) did not change significantly. Therefore, control of
temperature and pressure is the key to achieving a successful thermal bonding result which
means strong bonds with small deformation. Successful thermoplastic fusion bonding
requires not only the optimal condition of the temperature and pressure but also requires the
optimal condition of the polymer device, flat and clean bonding surfaces. The polymer
device needs to be checked for flatness since the device can be deformed by hot embossing
or UV modification. Additionally, the polymer needs to be dehydrated to avoid water vapor
effects during thermal bonding. The protocol of thermoplastic fusion bonding is shown in
Appendix E.
Thermoplastic fusion bonding results are shown in Figure 4.8 and the conditions for each
case in Figure 4.8 are shown in Table 4.2. Thermal bonding can be performed for multi
stacked devices for a modular system. Figure 4.9 shows the multi stack thermal bonding
which was accomplished in one thermal bonding process. It is also possible to stack thermal
bond multiple modules from previously thermal bonded individual modular devices or chips.
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(a)

(b)

(c)

(d)

(e)

(f)

Figure 4.8 Cross-sectional view of thermoplastic fusion bonding results for narrow micro
channels, 100 μm width and 20 μm depth for (a) and (b), and large dummy structures,
1000 μm width and 100 μm depth for (c) and (d). (a) and (c) show large deformation and
(b) and (d) show acceptable deformation. (e) and (f) show the top view of food color
filled micro channel. Conditions for each case are shown in below table.
Table 4.2 Conditions for each case in Figure 4.8
Cases

(a)

(b)

(c)

(d)

Temperature 110°C

105°C

Over 120°C

110°C

Pressure

20 psi

10 psi

20 psi

20 psi

time

90 min

90 min

30 min

30 min
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Micro channels in each chip

Figure 4.9 Thermoplastic fusion bonding of a multi-stacked device: thermal bonding of
five chips in the one bonding process (arrows indicate 20 μm depth of microchannels.)
Thermoplastic fusion bonding requires the device surfaces to be flat. Parameters such as
temperature, pressure, and time must be precisely controlled to achieve minimum
deformation and strong bonding. Current thermal bonding techniques use commercial ovens
and paper clips, custom-made spring jig, or weights to apply pressure [24]. However, the
precise pressure control is not easy with current methods and the temperature also depends
on the location of the device in the oven. Another alternative method for thermoplastic fusion
bonding is using a boiling liquid in a pressure cooker. The advantage of thermal bonding
using a pressure cooker is that the boiling temperature of the fluid is dependent on the vapor
pressure and its evaporation pressure can be used for thermal bonding. Moreover, precise
control of the parameters can be achieved simply.
4.4.2

Thermal bonding Using a Pressure Cooker

Figure 4.10 shows the basic concept and the modification to the pressure cooker for
thermal bonding. A commercial pressure cooker (Philippe Richard 8-Qt, China) was used for
polymer thermal bonding. The maximum operating condition of the pressure cooker was
higher than 15 psi pressure; the operating pressure for the thermal bonding application was
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under 10 psi. Therefore, using the commercial pressure cooker for thermal bonding did not
have any safety issues. The pressure cooker was connected to a pressure relief valve
(McMaster-Carr 48935K25, Cleveland, OH, USA) and pressure gage (McMaster-Carr
4088K29, Cleveland, OH, USA) through a pressure tube to control a pressure which
governed the boiling temperature. Another tube, a vent tube, was connected to the polymer

Pressure cooker
Pressure gage

Pressure tube

Pressure relief valve
Pressure tube
Vapor pressure

Vent tube
Boling water
Polymer
vacuum bag

Vent tube

Burner
(b)

(a)

Pressure gage

Pressure relief
valve

Vacuum
probe

Vent
tube
Vacuum
probe

Polymer devices

(e)
(c)
(d)
Figure 4.10 Thermoplastic fusion bonding using a pressure cooker: (a) schematic
representation of the pressure cooker modified for thermal bonding, (b) tube connections to
the system, (c) pressure control unit (enlarged picture of white dashed rectangular line in
(b)), (d) inner tube connection and vacuum probe, and (e) Vacuum polymer bag unit
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vacuum bag (Foodsaver T150-00011-002, Sunbeam Products, Neosho, MO, USA) using a
vacuum probe (Torr 353444, Torr Technologies, Inc., Auburn, WA, USA). The polymer
devices were placed in the plastic bags and sealed using a vacuum sealer (Foodsaver V2830,
Sunbeam Products, Neosho, MO, USA). The other end of the vent tube was opened to the
outside air. All tubes which were connected to the pressure cooker were sealed. The vapor
pressure in the pressure cooker compresses the polymer bag in the boiling solution. The
operating pressure was 3 psi, generating a temperature of 105°C for PMMA thermal bonding.
The operating pressure was not the same as the actual thermal bonding pressure which was
the pressure at the contact surfaces of the device, There are non-contacting areas, such as
channels, dummy structures, and reservoirs, between the device and the cover slip. The
actual pressure at the thermal bonding contact area is larger than the operating pressure. An
area ratio, the top or bottom area on the device divided by the contact area, is the
amplification ratio of the actual pressure at the contact surface. For example, if a 3 cm by 4
cm rectangular device with 6 cm2 of contact area is under 3 psi operating pressure, the actual
thermal bonding pressure across the contact area (or the bonding area) of the device will be 6
psi.
Thermal bonding using the pressure cooker gives better results compared to the previous
methods using a forced convection oven (VWR 1620, West Chester, PA, USA) because it
gives even or homogenous temperature on the part stack surface and more precise pressure
control. Figure 4.11 shows the results of thermoplastic fusion bonding using the pressure
cooker. In Figure 4.11, (a) a top view of two thermally bonded chips is shown and in (b) a
cross-sectional view of the chip. The operating condition was 3 psi which gave a 105°C
temperature in the bath and approximately an 8 psi actual bonding pressure. Even though the
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result of thermal bonding using the pressure cooker gives less deformation than the result
using a conventional oven, it is still not fully operational for demanding results yet. The
manual pressure control using the pressure relief valve needs to be replaced by a regulator for
automatic control.
Additionally, the pressure in the polymer device bag can be independently controlled by
controlling the pressure at the end of the vent tube. Thermal bonding of PC using boiling DI
water in a pressure cooker can be achieved; the boiling temperature can reach, for the PC,
around 150°C, by increasing the pressure in the pressure cooker. The pressure in the polymer
device bag can be controlled to obtain the required pressure by controlling the pressure via
the vent tube. More experiments are needed to identify conditions for achieving the minimum
deformation for the high flow rate device which has 5 ~ 10 μm depth and 1000 μm width
channel. Additionally, a new method of characterizing the deformation information is needed.

(a)

(b)

Figure 4.11 Results of thermoplastic fusion bonding using the pressure cooker: (a) top view
of the thermally bonded chips and (b) cross-sectional view of dummy structure, 300 μm
depth and 700 ~1000 μm width, in the PMMA chip
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4.5 Amine Functionalization and Antibody Immobilization on Polymer Surfaces
Amine functionalized and antibody immobilized PMMA surfaces were achieved to fix
the antibody on the polymer surface after UV modification and thermoplastic fusion bonding.
The UV modified PMMA, carboxylated surface, changes to an amine functionalized surface
(-NH2) by amine functionalization solution, ethylenediamine with EDC, 1-Ethyl-3-(3dimethylaminopropyl)-Carbodiimide, (Sigma, St. Louis, MO, USA) [6]. The protocol from
amine functionalization is shown in Appendix F. The PMMA surface changes to an amine
functionalized PMMA surface (amine terminated PMMA surface or aminated PMMA
surface) from the carboxyl group modified PMMA. The last step is an antibody
immobilization process to immobilize the antibodies on the PMMA surface. The EDC
solution containing antibodies produces the antibody immobilized PMMA surface from the
amine functionalized PMMA surface. The antibody, Anti-EpCAM-1 (Ab-1) Mouse mAb
(VU-1D9), was obtained from EMD Biosciences, Inc (Gibbstown, NJ, USA.) Once the
antibody immobilization was accomplished, the device could be stored at 4 °C for up to one
month and used to capture target cells. The details of the antibody immobilization process are
shown in Table 4.3.
Table 4.3 Protocol of Antibody Immobilization
1. Preparation of the antibody solution
10 μl antibody (1 μg/μl with PBS) + 0.0016 g EDC + 190 μl PBS
 Modified concentration method:
a. 0.8 g EDC + 95 ml PBS solution
b. Mix 10 μl antibody with 190 μl above solution

2. Flow the antibody solution into the channel using the syringe pump.
3. Incubate the antibody solution overnight at 4°C
(Incubation can be done for 2 hours at room temperature)

4. Flow PBS into the channel to rinse the antibody solution
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4.6 Control Experiments
To achieve optimal processes (UV modification, amine functionalization, and antibody
immobiliation of the PMMA surfaces), control experiments were performed with three types
of PMMA, multiple exposure times, and several process cases. The PMMA samples were
1/16 inch thickness of MC grade PMMA from Plexiglas (Altuglas Int`l., Philadelphia, PA),
1/8 inch thickness of Cyro Acrylite FF grade PMMA (Evonik Cyro, Parsippany, NJ), and 2
mm thickness of Vistacryl CQ grade PMMA from Vista Optics (Widnes Cheshire, UK),
shown in Table 4.4. The control experiments were done on an unsealed PMMA surface.
To test the antibody immobilization performance, a fluorescein (FITC) conjugated
second antibody (a fluorescein-conjugated affinipure donkey anti-mouse IgG, Jackson
Immunoresearch Laboratories, Inc., West Grove, PA, USA) was bound to the first antibody,
which had previously been coated on the PMMA surface using the antibody immobilization
process, and the FITC intensity was measured by fluorescence microscope (Leica DM RXA2,
Leica Microsystems Inc., Bannockburn, IL, USA). MCF-7 cells were captured on the first
and second antibody-coated PMMA surfaces. However, counting the captured MCF-7 cells
did not give any reliable information due to an inconsistent rinsing process. Moreover,
binding sites on the first antibody for the MCF-7 cell may be occupied by the second
antibody. The number of the remaining MCF-7 cells was random after a PBS rinse.
For the second antibody binding process, the FITC conjugated second antibody (4 mg/ml)
was mixed with PBS (dilution ratio was 1:50). The solution was put on the first antibody
immobilized PMMA surface overnight at 4°C for incubation. After antibody incubation, the
solution was blown off using nitrogen gas, followed with a PBS rinse. Figure 4.12 shows the
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PMMA preparation for the control experiments. Each PMMA sheet was divided into five
different UV exposure time zones.
Table 4.5 indicates the process steps performed for each case. For example, for „Case 1‟
all steps, including UV modification, first antibody functionalization, and FITC conjugated
second antibody functionalization, and MCF-7 cell capture with PBS rinsing were performed.
For „Case 4‟ only the first and second antibody functionalization steps and MCF-7 cell
capture without the UV modification process were carried out. Figure 4.13 shows the results
of the control experiments. The exposure time of the fluorescence light on the fluorescence
microscope was constant for all cases and the average FITC intensity was measured over a
consistent area on each PMMA surface. The units of the FITC intensity were arbitrary.
Table 4.4 PMMAs for control experiments
PMMA Grades
MC
FF
Vistacryl CQ

Brand

Thickness

Plexiglas
Cyro Acrylite
Vista Optics

1/16 inch
1/8 inch
2 mm

Figure 4.12 PMMA samples for the control experiments
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Figure 4.13 shows that the FITC intensities for all cases were usually increased as the UV
exposure time increased. The FITC intensity of Cases 1 and 4 with a 5 minute UV exposure
time shows a sudden intensity increase for an unknown reason. It also shows that Cases 1, 4,
6, and 7 have higher intensities than for all other UV exposure times. It is because these
cases were used for the FITC conjugated second antibody immobilization. Even though the
amine functionalization and the first antibody immobilization for Cases 6 and 7 were not
accomplished, they still show a high FITC intensity. This is possibly due to non-specific
binding of the second antibodies with the EDC coupling on the PMMA surface. The nonspecific binding phenomena also happen for the first antibody immobilization. It explains
Case 4, which omitted the amine functionalization, and still shows a high intensity. Although
Case 1, theoretically, should have the highest FITC intensity, the FITC intensity of Case 1
was not significantly higher (or lower) than that of the Case 4. However, the graphs indicate
background noise was also increased with greater UV dose. The Case 2, Case 3, and Case 8,
which does not have FITC dye on the PMMA surface, point that longer exposure gives
higher intensity. Therefore, 5 minutes UV exposure time was enough for antibody
immobilization. To investigate the effect of longer UV exposure times, 60 minutes UV
exposure time was also tested. The surface of the CQ PMMA was not visibly damaged from
over 60 min UV exposure unlike the other PMMA, both the MC and FF grades, which
required limited exposure times (8 min) to avoid surface damage. These results are probably
related to molecular weight. For the CTC capture, the FF and MC grades were used with 6~8
min UV exposure because the price of MC or FF PMMA is much lower than the CQ PMMA.
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Table 4.5 Control experiment cases based on the execution of the each process step (UV
modification, amine functionalization, antibody immobilization, and target cell capture
process)
Process

Amine
Functionaization

FITC Conjugated
2nd Antibody

1st Antibody

Case 1

x

x

Case 2

x

x

Case 3

x

x

MCF-7 Capture
and PBS Rinse
x
x
x

Case 4

x

Case 5

x

x

x
x

Case 6

x

Case 7

x

x

Case 8

x
FITC Intensity - PMMA MC

800

FITC Intensity [Arbitrary]

700

600

500

400

Case 1
Case 2
Case 3
Case 4
Case 5
Case 6
Case 7
Case 8

300

200

0

5

10

15

20

UV Exposure Time [Minutes]

(a)
Figure 4.13 FITC intensity from five UV exposure time, three different PMMA types, and
six cases
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FITC Intensity - PMMA FF
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(b)
FITC Intensity - PMMA CQ
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Case 8
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20
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(c)
Figure 4.13 FITC intensity from five UV exposure time, three different PMMA types, and
six cases
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4.7 Sample Preparation
Circulating tumor cell (CTC) research requires an extremely low target cell concentration
because the frequency of the CTCs in human blood is very low, less than one cell per
milliliter. However, it is difficult to prepare samples for rare CTC capture experiments since
common cell or cancer research typically uses at least 106 cells per milliliter sample. One
option for preparing the rare cell samples is the dilution method. However, the dilution
method, using a hemacytometer, cannot guarantee the cell concentration and is not
recommended for fewer than 1000 cells per milliliter. It is important to use an exact number
of target cells because the impact of the wrong input number of CTCs will cause a large error.
Another option is a commercial cell counter or fluorescence activated cell sorter. However,
it is not suitable for single or rare cell collection since those instruments require fluorescence
labeling and need cell concentrations of more than 1000 cells/mL. Moreover, the
fluorescence labeling and laser illumination stresses the cells. Protocols for the isolation of
pure cells from colonies were introduced, but it is a complicated and lengthy process not
suitable for microdevice applications [25, 26]. A method for counting small numbers of cells
was introduced by Badders, et al. in 2008 [27]. However, it was not suitable for less than
1000 cells/mL. Single cell analysis methods were introduced in previous research, but were
focused on specific applications with a complicated device for each use [28, 29]. Preparation
of samples for rare cell capture experiments, such as CTC capture research, cannot use
previous methods because the number of target cells should be exact to accurately assess the
effectiveness of very rare cell capture.
An easy and simple protocol for collection of single or exact numbers of cells was
developed to overcome the limitations of the previous methods. A hemacytometer or PMMA
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cell collection chip with a silica capillary and syringe were used for collection of precise
number of cell. A PMMA sheet was directly micro milled to fabricate the cell collection
chips. The depth of the cell collection wells can be adjusted by using different size capillaries
to support a cover glass to accommodate different size target cells. Figure 4.14 shows the
PMMA cell collection chips with supporting capillaries. Figure 4.14 (a) is a single-wall cell
collection chip and Figure 4.14 (b) is a multi-wall cell collection chip. The PMMA chip in
the Figure 4.14 (b) reduced the cover glass bending which occurred due to the fixing of tapes
on the sides of the cover glass, and it increased the number of cell collection chambers.
For single cell collection, polyimide at the end of commercial capillary tubes was
selectively removed by flaking off the polyimide coating over a 600°C flame. Cells were
then visible in the capillary and the capillary was movable in the hemacytometer or cell
collection chip. The other end of the capillary was connected to a syringe. Cells were injected
into the cell collection chip at low concentrations, approximately 103 ~ 104 cells/mL. The
modified capillary was inserted into the well under a microscope. Once the capillary was
located near a target cell, the syringe was withdrawn to enable collection of the target cell in
the capillary. The number of collected cells can be visually confirmed during the collection
process. After collection of the desired number of target cells, the remaining cells and
capillary surface were washed out with PBS. Moreover, the collected cells can be easily
transferred to any desired location, such as a microdevice, cell culture chamber, or micro
vials, for any further processing without any cell loss.
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(a)

(c)

(b)

(d)

(e)

Figure 4.14 PMMA cell collection chips with a pair of supporting capillaries which are
located in a micro milled grooves to support a cover glass, polyimide removed cell collection
capillary can be inserted under the cover glass and between the supporting capillaries. (a)
Single wall cell collection chip, (b) multi wall cell collection chip, (c) schematic illustration
the cell collection chip, (d) cover glass supporting capillary area, and (e) cell collecting
capillary area.
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Figure 4.15 shows the collection of a single MCF-7 cell using a hemacytometer and
polyimide-coated fused-silica capillary under the microscope. The blue circles in Figure 4.15
indicate a collected single target MCF-7 cell. The capillary was clearly visible and easily
movable with the polyimide removed. The method for single cell sample preparation is
applicable not only for CTC research, but any other rare cell analysis research. Figure 4.16
shows the collection of a single human adipose-derived stem cell (hASC) using a cell
collection chip.

Figure 4.15 Collection of single cell using a silica capillary (OD=105 μm) and syringe (5 μl)
in a 100 μm depth hemacytometer.
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Time = 0 seconds

Time = 3 seconds

Time = 6 seconds

Time = 9 seconds

Figure 4.16 Single cell collection using cell collection chip; Polyimide was removed from the
capillary (OD=190 μm), which was used to collect an human adipose-derived stem cell
(50~100 μm diameter) in a 195 μm deep cell collection chip. The target stem cell is close to
the capillary and drawn into the capillary. Because the collected cell in the capillary is above
of the observation area, it is not visible in the capillary when the time was 9 seconds.
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4.8 Target Cell Capture
The target cells can be stained with fluorescence to distinguish them from blood cells or
other control cells. The MCF-7 cells were stained with 4',6-diamidino-2-phenylindole (DAPI.)
DAPI has an excitation wavelength of 359 nm of and emission wavelength of 461 nm. Figure
4.16 shows the DAPI stained MCF-7 cells. In Figure 4.17 (b), the PMMA channel was
coated by anti-EpCAM and the FITC conjugated second antibody. From the same location
and same cell, different images were achieved using FITC or DAPI filters.

(a)

(b)
Figure 4.17 Fluorescence stained MCF-7 cell: (a) DAPI stained MCF-7 cell in the
microscope glass slides and (b) DAPI stained MCF-7 cell in the antibody immobilized
PMMA channel
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The target cells needed to be transferred into the cell capture zone, an antibody
immobilized channel for most cases, without cell loss. Moreover, the cell flow should be
controlled for maximum cell recovery rate. The anticipated optimum mean velocity of the
EpCAM expressing target cells was 1 ~ 2 mm/s.
Air bubbles were removed to avoid blockage of the cells by air bubbles. Air bubble
formation originates from outside of the device through the capillary or it can be generated
inside of the device due to a locally low pressure at sharp corners. Preexisting air bubbles in
the dead volume were also a concern. For the cell capture experiments, DI water and PBS
were degassed using a sonicator (Branson Ultrasonics Corporation, Danbury, CT, USA) for
over 30 minutes. Trapped air in the microdevice was eliminated by alternately pushing and
drawing with the syringe [30]. Figure 4.18 shows the removal of air under the microscope.
The cell solution was driven using a syringe pump. The average velocity of the pressure
driven fluid was controlled by flow rate control. Figure 4.19 shows an initial experiment of
the MCF-7 cell capture in the microchannel (100 μm width and 20 μm depth) without the
precise cell collection process. Target cells were stained with DAPI (or trypan blue).

Figure 4.18 Elimination of air bubble by suction and pushing under the microscope
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(a)

(b)
Figure 4.19 MCF-7 cell capture in the antibody immobilized microchannel: (a) DAPI and
trypan blue stained MCF-7 Cells and (b) DAPI stained MCF-7 cells
The cell solution was infused into the antibody immobilized channel. The average
velocity of the MCF-7 cells was 2 mm/s More than 106 cells in PBS were used and a PBS
rinse at 10 mm/s followed to confirm the antigen/antibody binding and to remove any
material that was binding non-specifically.
A pristine PMMA channel also was used for a control cell capture experiment. No cells
were captured in the pristine PMMA channel.
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The rare cell capture experiments were accomplished using the rare cell collection
method. Figure 4.20 shows the process and results. A total of 14 target cells were collected in
the cell collection capillary. The collected cells in the cell collection capillary were delivered
into the microchannel through the guide capillary. Before inserting the cell collection
capillary, the air bubbles in a chamber or reservoir were removed by continuous infusion or
suction at the inlet and outlet of the channel. Once the cell collection capillary was inserted in
the PMMA device, the syringe pump (NE-500, New Era Pump systems, Inc., Wantagh, NY,
USA) delivered the target cells with an average velocity of 2 mm/s.
All 14 cells were collected, delivered, and captured very near the channel inlet. PBS rinse
at more than 20 mm/s followed. Even though some of the cells were relocated in the channel
during the rinsing, they did not move far away from the initial point. The relocation of the
captured cells during rinse may due to too high shear flow or pressure in the narrow channel
which pushes the captured cell. The MCF-7 cells barely can flow in the 20 μm channel
because the size of the MCF-7 cells is very close to the channel size or sometimes larger.
Even through the rare target cell capture was successful, the flow rate was much lower than
the desired value. The flow rate for the rare cell capture was 0.24 μL/min but the desired flow
rate is 0.75 mL/min. Therefore, a new cell capture concept or design for the high flow rate,
0.75 mL/min, was necessary and the high flow rate design, introduced in section 3,
developed.
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(a)

(b)

(c)

(d)
Figure 4.20 Rare cell capture: (a) elimination of the trapped air bubbles, (b) inserting cell
collection capillary, (c) cell capture without any target cell lost, and (d) captured cells in
the channel after PBS rinse.
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4.9 High Flow Rate Device
High flow rate devices were designed based on the simulation results and fabricated on
PMMA sheet using micro milled mold insert and hot embossing process. Sealing of the
PMMA HFRDs was the key to HFRD fabrication due to the very low aspect ratio side
channel and a variation of the substrate thickness. Sealing was performed using thermoplastic
fusion bonding (TPFB), pressure sealing, or PMMA spin coating (PSC) technique. Pressure
control for the TPFB was tried with paper clip, custom made spring jig, weights, a pressure
cooker, and a local pressure control method. A forced convection oven (VWR 1620, West
Chester, PA, USA) or hot plate also was used for temperature control. The pressure sealing
method used two pieces of thick glass to press the HFRD and cover sheet together with paper
clips to apply pressure. The PSC method used PMMA beads and PGMEA (propylene glycol
monomethyl ether acetate, Sigma-Aldrich, St. Louis, MO.) The custom-made spring plunger
assisted jig and local pressure control method are explained in Appendix A. The antibody
was monoclonal anti-human EpCAM (Monoclonal Antibody Human EpCAM/TROP1 MAb
(Clone 158206), Mouse IgG2B, R&D Systems, Inc., Minneapolis, MN, USA) to achieve
high specific antigen/antibody binding.
4.9.1

High Flow Rate Device Version One (HFRD1)

High flow rate device version one, which had 10 µm deep side channels, was designed as
a combination of modified case N3 (Chapter 3.4.2.2) with a longer channel (Lv = Ls = 6250
µm) and modified case C (Chapter 3.4.2.1) with a longer channel (Lt = 6550 µm) to reduce
velocities. The sealing of the HFRD1 was attempted using thermoplastic fusion bonding and
a glass jig after UV modification. The forced convection oven (VWR 1620, West Chester,
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PA, USA) was used to control the bonding temperature. Paper clips and weights were used to
control the pressure for TPFB. The pressure cooker was also used for sealing of HFRD1.
Figure 4.21 shows the PMMA HFRD1. There are four deformation indicators, red dotted
rectangles, at the four corners on the device. Each deformation indicator had four chambers
which were 10 µm or 15 µm deep and 1000 µm wide chambers to check the deformation
information with the naked eye. Most of the results showed that the pressure distribution was
not even.
Figure 4.22 shows the schematic of the HFRD1 and the sealing results. The forced
convection oven and weight were used, with a bonding temperature of 105°C, pressure was
8.8 psi, and time was 24 hours. The first section of the HFRD1 has a collapsed area on the
side channel even though the second section shows good bonding without the collapse of the
side channel. This is due to the uneven pressure distribution over the whole surface of the
HFRD1. Results for different bonding conditions are shown in Figure 4.23. The time was an
important factor for this very low aspect ratio channel or device (1/70) because the only
difference between Figure 4.22 (b) and Figure 4.23 (b) is the operating time. However, the
results for the same condition were not always consistent and sealing of the very low aspect
ratio channel/device is still a challenge.

Unbonded area

Figure 4.21 Thermoplastic fusion bonding using oven: deformation indicator shows uneven
pressure distribution.
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Depth of Side Channel: 10 μm

First section

Second section

Part

(a)

(b)

(C)
Figure 4.22 High flow rate device version one: (a) Schematic drawing of HFRD1, and
sealing results (105 °C with 8.8 psi for overnight) on (b) the first section of HFRD1 and (c)
the second section of the HFRD1 (dark fields or arrows indicate bonded/collapsed area)
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(a)

(b)

(c)
Figure 4.23 Results of TPFB with different conditions using oven for temperature and
paper clips or weight for pressure (a) 104°C with two paper clips (67 psi) for 1 hour, (b)
105°C with weight (8.8 psi) for over 1.5 hours, and (c) 105°C with weight (10.12 psi) for
overnight (dark fields or arrows indicate bonded/collapsed area.)
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The pressure cooker was also used to the seal the HFRD1 devices. It gave better results
with 2.5~3 psi operating pressure, with a resultant temperature of 104°C ~ 105°C, compared
to the oven-based TPFB, but it still produced uneven sealing. Figure 4.24 shows a prototype
HFRD1 sealed using the pressure cooker at 3 psi (=105°C) with DI-water.
The third method was pressure sealing. The HFRD1 devices and cover sheet were
sandwiched between two pieces of thick glass and pressed by paper clips. One side glass had
holes for capillary connections. Figure 4.25 showes the pressure sealing demonstration and
leakage experiments.
Leakage tests of the HRFD1 prototypes were done using the pressure sealing method
with food color. Results are shown in Figure 4.26. Pressure sealing method gave an
acceptable seal. There was no leakage except at the highest flow rate (0.75 mL/min.)

Figure 4.24 Sealed HRFD1 using pressure cooker
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(a)

(b)

Figure 4.25 Sealing of the HFRD1 using (a) pressed sealing method and (b) leakage
experiment with food color

(a)

First Section

Second Section

(b)
Figure 4.26 Leakage test of HFRD1: (a) Schematic drawing of HFRD1 and (b) leakage test
with food color
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Target cell capture experiments with the HFRD1 devices were performed without
antibody immobilization process. Target cells escaped through the 10 µm deep side channel
and many target cells clogged the side channel. Figure 4.27 shows the clogged target cells in
the side channel. The target cells escaped because of inappropriate cell conditions; fixed and
stored in 70% ethanol over months, and the deep side channel. Even though the cell
conditions were not appropriate, target cells should not escape freely. So, the depth of the

Side Channel

Main Channel

Side Channel

Drain Reservoir

Drain Reservoir

side channel needed to be reduced.

Figure 4.27 Target cell capture using HFRD1: clogged target cells on the side channel after
target cell escaping through the side channel (Red arrows indicate clogged target cells)
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4.9.2

High Flow Rate Device Version Two (HFRD2)

The HFRD2 was designed based on the simulation results and tested because the HFRD1
had target cell loss and clogging of the side channel. The HFRD2, a combination of cases G4
and S4 (Chapter 3.4.3), had a 5 µm deep side channel and a larger inlet cross-sectional area
than HFRD1 to avoid target cell loss. The sealing of the HFRD2 was tried with TPFB and
PMMA spin coating (PSC) method. TPFB sealing method used paper clips, local pressure
control, or weight in a forced convection oven (VWR 1620, West Chester, PA, USA). Figure
4.28 shows the local pressure control chip which has a symmetric design for HFRD2 to apply
the pressure on the only contact area by pressing on the cover sheet. The applied conditions
were 93~105°C and 5~20 psi. The results of the TPFB method were not acceptable and not
consistent. The side channels were blocked by deformation during TPFB.
The PMMA spin coating (PSC) method for the HFRD2 yielded good results. PMMA
beads (molecular weight: 75000, polysciences, Inc., Warrington, PA) was dissolved in the
PGMEA solution after three days mixing using a stirer. A mixing ratio of 2.5~5% (w/w) was
used and the output filtered with a 0.2 µm membrane syringe filter. The 2.5% PMMAPGMEA solution was loaded on a PC sheet (4 inch diameter and 500 µm thickness) for spin
coating.

Figure 4.28 (a) Local pressure control chip for TPFB
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Hot Plate
HFRD
PSC_PC

Glass
Figure 4.29 (a) PSC_PC sealing method using a roller on a hotplate

Three steps of spin coating angular velocity were used. The first step was 500 rpm for 5
seconds, the second step was 4500 rpm for 60 seconds, and the last step was 1000 rpm for 60
seconds. The PMMA spin coated PC (PSC_PC) sheet was put on a piece of glass for 5
minutes at room temperature to dry and vaporize the solvent slowly and then placed on a
55 °C hot plate. On the hot plate the HFRD2 and PSC_PC was sealed using a roller
(Speedball, Art Products Co LLC, Statesville, NC, USA.) Figure 4.29 shows the PSC_PC
sealing method using the roller. The thickness of the dried PMMA spin coated layer was less
than 150 nm because the thickness of 5% PMMA-PGMES solution gave 150 nm with 75,000
molecular weight PMMA after 4500 RPM spin coating and baking.
A new capillary fitting method was introduced for easy and quick capillary connection.
The inlet and outlets of the device were drilled using size #70 or #71 drill bits (Carbide drill,
Kennametal Inc., Latrobe, PA USA) at 5000 rpm. The inlet and outlet ports could be tapered
using a broken micro drilling bit. Pushing and rotating the broken drilling bit by hand in the
inlets or outlets created tapered inlets or outlet ports. The capillary, 1/32 inch PEEK tube
(IDEX Health & Science LLC, Oak Harbor, WA), could be directly connected with the
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tapered inlet and outlets without any other additional material such as, glue or epoxy. There
was no leakage during the experiments because it was sealed by friction and fixed tightly
between the capillary and tapered inlets or outlets. The maximum fitting pressure was not
tested but it held enough pressure for any microdevice uses. Figure 4.30 shows the new
capillary connection method and the PSC sealed and capillary connected HFRD2.
The sealed HFRD2 devices were tested for the escape of target cells without antibody
immobilization. Without antibodies the HFRD2 was only a size based target cell capture
system. The target cells were in PBS and infused using a syringe pump. To test for the escape
of target cells at each section and location, two of three outlets were closed using end closed
10 µL pipette tips. The target cells could escape through the first section side channel at 25
µL/min; 45 µL/min in the second section side channel also permitted the target cell escape.
Figure 4.31 and Figure 4.32 show the target cells in the side channel or drain reservoir.

Broken Drill Bit

(a)

(b)
Figure 4.30 Capillary connection method: (a) Tapered inlets and outlets could be made with a
broken drill bit (inserted picture) and (b) direct capillary connection of HFRD2 without
additional adhesive or bonding material
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(a)

Main Channel

Side Channel at the First Section

Drain Reservoir
(b)
Figure 4.31 Target cells that passed into the side channel; (a) Inlet flow rate was 25 µL/min
and only one side outlet was opened (other outlets, right side outlet and main outlet, were
closed.), (b) Target cells were found in the drain reservoir and on the side channel.
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(a)

Drain Reservoir
Supporting Post

Side Channel at the Second Section

Target Cells

Main Channel

(b)
Figure 4.32 HFRD2 target cell loss in the second section; (a) Inlet flow rate was 45 µL/min
and only main outlet was opened (The first section outlets were closed.), (b) Remaining
target cells in the side channel and in the main channel after rinse (target cells in the reservoir
were washed out.)
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4.9.3

High Flow Rate Device Version Three (HFRD3)

High flow rate device version three (HFRD3) was designed and fabricated based on the
simulation results and experiments with the earlier prototypes. The inlet velocity could be
reduced because the inlet cross-sectional area was increased. The inlet velocity of the
HFRD1 was 278 mm/s, HFRD2 was 96 mm/s, and HFRD3 was 19 mm/s to match the target
flow rate, 0.75 mL/min. The HFRD3 devices were sealed with thermoplastic fusion bonding
(TPFB) and the PMMA spin coating method after UV modification. TPFB for the HFRD3
was performed using paper clips, weights, the custom-made plunger spring assisted jig, and
local pressure control method. Conditions for TPFB were 93~105 °C and 5~20 psi. The
range of the temperature and pressure was narrowed down to 101~103 °C and 5~10 psi based
on the TPFB results. However, the results of the TPFB were not consistent and local
deformation was observed in most cases even through multiple tools and a variety of
conditions were evaluated. Figure 4.33 shows the sealed HFRD3 after TPFB. The main
channel or side channels were locally collapsed. The supporting posts in the main channel
and in the side channels could not properly prevent the deformation for most cases.
The reason for the local deformation was an uneven pressure distribution over the whole
surface during TPFB. The main reason for the uneven pressure distribution was thickness
variation of the hot embossed PMMA devices. The thickness variation of the hot embossed
HFRD3 was 40 ~ 80 µm and compared to variation of pristine PMMA sheet (1/16 inch
thickness) of 6 ~ 8 µm. More than three of the HFRD3 devices were investigated and the
range of the thickness variations were 40 ~ 80 µm. The average thickness variation of the hot
embossed HFRD3 devices is shown in Figure 4.35. The center area is 70 µm thicker than
side area on the HFRD3. The thickness variation was caused by a nonuniform bottom press
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plate in the Jenoptik HEX 02 (Jena, Germany) system at the Center for Advanced
Microstructures and Devices (CAMD) at LSU. Because of this thickness variation, the TPFB
of the HFRD3, which has 5 µm depth side channel, was not successful.

Figure 4.33 HFRD3 after thermoplastic fusion bonding

Bonded Area

Supporting
Posts

(a) Deformed and blocked main channel

(b) Properly supported main channel

Bonded Area

Side Channel
Side Channel

(c) Blocked side channel

(d) Well supported side channel

Figure 4.34 Results of sealing using TPFB for HFRD3: (a) and (b) main channel area and (c)
and (d) side channel area
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Figure 4.35 Thickness variation of the hot embossed HFRD3

The PMMA spin coating (PSC) method was tried for sealing of the HFRD3 to overcome
the thickness variation. The PSC sealed HFRD3 is shown in Figure 4.36. The depth of the
side channel after sealing was examined under a microscope. It was roughly 5 µm but hard to
define the exact number due to the rounded edge on the cross-sectional surfaces. After
sealing, the HFRD3 was amine functionalized and antibody immobilized.
Target cell capture experiments were accomplished after UV modification, amine
functionalization, and antibody immobilization processes. Using a hemacytomer 100 live
MCF-7 cells were prepared and spiked in PBS. The cells in PBS were drawn through the
chips using syringe pumps. The flow rate for the target cell capture was 120 µL/min. The
rinse was completed with PBS at 1200 µL/min after the capture of the target cells. The
captured MCF-7 cells were fixed with -20 °C methanol, and then stained with DAPI. The
captured MCF-7 cells were counted using a fluorescence microscope (Nikon Eclipse E600,
Nikon Instruments Inc., Melville, NY). The average recovery rate of the MCF-7 cells in PBS
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was 85%. In most cases, the target cells were captured at the side channel entrance area.
Figure 4.37 shows the flow rate conditions and captured MCF-7 cells in the HFRD3.

Main Channel

Drain Reservoir
Supporting Posts

Clogged Area on the Side Channel
Side Channel

Side Channel

Main Channel

Drain Reservoir
(a)

(b)
Side Channel

Cover Sheet
Side Channel
Drain
Reservoir

Main Channel

HFRD3

Main
Channel

Drain
Supporting Post on
Reservoir
the Side Channel

Supporting Post
(c)

(d)

Figure 4.36 Sealing of HFRD3 using PMMA spin coated PC (a) Top view of side channel area
without PMMA solution clogging, (b) Top view of side channel area with PMMA solution
clogging, (c) Cross sectional view of side channel at the red line in (a), (d) Enlarged picture of
red dotted rectangular in (c)
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60 µL/min
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(a)

Main Channel
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Side Channel
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Main Channel
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Side Channel
Side Channel
Drain Reservoir
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Figure 4.37 Target cell captured using HFRD3: (a) flow control at three outlets and (b)
captured MCF-7 cells on the side channel entrance from PBS solution
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Human red blood cell (RBC) tests were performed to confirm that the RBCs escaped
through the side channel in the HFRD3. The RBCs were purchased from Innovative
Research (Novi, Michigan USA.) The RBCs did tend to pass through the side channel.
Figure 4.38 showed the RBCs flowing through the side channel. The red arrows indicate
clumped RBCs in the side channel. Some of RBCs were locally clumped and partially
blocked the side channel which causes pressure and velocity increase in the side channel. The
RBC clumping may happen due to the coagulation or aggregation of the RBCs. Higher
concentrations of RBCs and higher velocity gives more RBC clumps. Multiple
concentrations (100%, 45%, 20%, 10%, and 5%) were tested and heparin (BD 8362834,
Vacutainer with Sodium Heparin - 158 USP units, Franklin Lakes, NJ USA) was added.
Higher concentration of the heparin and lower concentrations of RBCs gave better RBC flow
in the side channel since it reduces the coagulation/aggregation and clumping of the RBCs.
After the initial RBC flow tests, the HFRD3 was rinsed with PBS. Any RBCs remaining in
the channels were fixed with -20 °C methanol and stained with DAPI which stains only
nucleated cells. Some of the captured cells were stained with DAPI even though RBCs do not
contain nuclei. DAPI stained individual cells were found at the side channel entrance region.
The DAPI stained and clumped, coagulated, or lysed RBCs located in the side channel. The
reason for the nuclear stain with RBCs is not clear. It may be due to under-developed RBCs
or white blood cells which were not eliminated during the separation process. Figure 4.39
show the stained cells (RBC or WBC) at the side channel entrance area and clumped RBCs
in the side channels. Yellow arrows indicate individually stained cells at the side channel
entrance and red arrows represent clumped RBCs in the side channel. The blue arrows show
unstained and unknown cells.
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Figure 4.38 RBCs flowing through 5 µm depth side channel: (a) flowing without RBC
clogging or clumping and (b) lightly clumped RBCs in the side channel
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Figure 4.39 DAPI stained cells during RBC tests: (a) individual and heavily clumped RBCs
and (b) individual and medium clumped RBCs
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Target cell capture from RBCs was accomplished. Target cells, MCF-7 cells, were
harvested and stained with membrane fluorescence (PKH67, Sigma-Aldrich, St. Louis, MO)
to overcome the RBC staining issue. The target cells were diluted until there were 20~30
cells in 9 chambers (0.9 µL) in a hemacytometer and counted more than 5 times to minimize
an error in the cell concentration. To collect 100 MCF-7 cells, the sample volume (3 µL ~ 4.5
µL) was calculated and collected using a pipette. The collected cell solution was spiked into
the RBCs. The RBC solutions containing target cells were delivered to the HFRD3 device
using syringe pumps. After capturing the CTCs and washing with PBS, the captured CTCs
were counted under a fluorescence microscope. Figure 4.40 shows the target cell capture
experiment configuration.

Figure 4.40 Target cell capture experiment configuration
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The flow rates for the target cell capture was 150 µL/min and 750 µL/min and the
concentration of the RBCs was 40~42%. Three experiments were done for each case. The
target cells were in viable condition. For the case of 150 µL/min, the flow rate in the two side
outlets (Wr and Wl) was 45 µL/min and the flow rate of the main outlet (Wo) was 60 µL/min.
Figure 4.41 shows the flow rate control for the HFRD3. The sample mean target cell
recovery rate was 81% with a sample standard deviation of 3.46 (Confidence Level (95.0%)
= 3.92.) Table 4.6 shows the results of CTC capture from 100 viable MCF-7 cells at 150
µL/min. Figure 4.42 shows the target cell recovery rate at 150 µL/min. Figure 4.43 shows the
captured target cells in the HFRD3 device. Most of the target cells were captured near the
entrance of the side channels at 150 µL/min.

Wo

Wr
Wl



Wr: Withdraw Flow Rate of the Right Side
Channel Outlet



Wl: Withdraw Flow Rate of the Left Side
Channel Outlet



Wo: Withdraw Flow Rate of the Main
Outlet

Figure 4.41 Flow rate control of the HFRD3

Table 4.6 CTC capture from 100 viable MCF-7 cells at 150 µL/min
Sample Number
1
2
3

Captured CTCs Number
79
79
85
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Recovery Rate (%)
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81

90
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60
50
40

s.d. = 3.46

30
20
10
0

150

Flow Rate [µL/min]

Figure 4.42 Target cell recovery rate with 100 viable MCF-7 cells at 150 µL/min (s.d.:
sample standard deviation)
Drain Reservoir

Drain Reservoir
Side Channel

Side Channel

Main Channel

Main Channel

Main Channel

Main Channel

Side Channel
Side Channel
Drain Reservoir

Drain Reservoir

Figure 4.43 Captured target cells at the side channel entrance area in HFRD3 from 100 viable
MCF-7 cells at 150 µL/min
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High flow rate target cell capture was accomplished with 100 or 13~16 viable MCF-7
cells with 40~42 % RBCs at 750 µL/min (Wr = Wl = 200 µL/min and Wo = 350 µL/min.)
The captured target cells were found not only at the side channel entrance area or in the main
channel but in the side channel or in the drain reservoirs, which was not observed at 150
µL/min. Figure 4.44 shows the target cells captured at the side channel entrance area, in the
side channel, or in the drain reservoir in case of the 100 viable MCF-7 cells with 750 µL/min.
The sample mean (mean) recovery rate was 76% and sample standard deviation (s.d.) was
6.56 (Confidence Level (95.0%) = 7.42) except target cells trapped with RBCs in the drain
reservoirs behind the side channels. The recovery rate was 85.67 ± 11.7% (mean ± s.d.) and
confidence level (95.0%) = 13.3 if the trapped target cells in the drain reservoir were
included. Table 4.7 shows the captured CTCs at each location. Figure 4.45 shows the
recovery rates with 150 µL/min and 750 µL/min.

Drain Reservoir

Main Channel

Side Channel

Side Channel

Drain Reservoir

Main Channel

Figure 4.44 Captured target cells in HFRD3 at 750 µL/min (a) at the side channel entrance and
(b) in the side channel (blue arrow) and in the drain reservoir (red arrow)
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Table 4.7 Location of captured MCF-7 cells from100 CTCs
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), 100 Live MCF-7 Cells stained w/ PKH67
100 CTCs

Captured
1st Section 1st Section
CTC Number Side Channel Main Channel

HFRD3#310
(42% RBCs)
HFRD3#306
(40% RBCs)
HFRD3#303
(40% RBCs)

2nd section 2nd Section
Side
Main
Channel
Channel

1st Section
Reservoir

2nd Section
Reservoir

83

52

2

29

0

16

0

75

24

15

11

25

6

0

70

45

11

14

0

7

0

100

CTC Recovery Rate

90
81 ± 3.46%

76 ± 6.56%

Recovery Rate [%]

80
70
60
50
40
30
20
10
0

150

750
Flow Rate [µL/min]

Figure 4.45 Target cell recovery rate: 81 ± 3.46% (mean ± s.d.) for 150 µL/min, and 76 ±
6.56% (mean ± s.d.) for 750 µL/min
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Samples which were prepared statistically using a hemacytomter cannot provide the
precise number of target cells. To overcome the uncertainty of the target cell numbers, exact
numbers of target cells was used for target cell capture using single cell collection chip and
capillary, shown in Chapter 4.6. The exact number of target cells was collected and spiked in
the 40~42% RBC solution. The sample mean number (mean) and sample standard deviation
(s.d.) of collected target cells was 14.67 ± 1.53 (mean ± s.d.) Different numbers of CTCs
were collected due to slow response time of suction during target cell collection. The
recovery rate was 84.94 ± 19.8% (mean ± s.d.) without trapped cells in the drain reservoir
and 89.58 ± 18.0 (mean ± s.d.) with trapped cells in the drain reservoir. Table 4.8 shows the
captured CTCs at each location. Table 4.9 shows the percentage of captured target cells for
each location (converted form Table 4.8.) Appendix D shows pictures of captured target cells
for 10 CTC cases.
Table 4.8 Number of captured target cells for each location in the high flow rate device3
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of Live MCF-7 Cells stained w/
PKH67
Small # of Used CTC 1st Section
1st Section 2nd section 2nd Section
1st Section 2nd Section
CTCs
Number Side Channel Main Channel Side Channel Main Channel Reservoir
Reservoir
HFRD3#322
15
5
2
8
0
0
0
(40% RBCs)
HFRD3#312
13
8
0
4
0
0
1
(40% RBCs)
HFRD3#315
16
7
0
3
0
1
0
(42% RBCs)

Table 4.9 Percentage of captured target cells for each location (Converted from Table 4.8)
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of Live MCF-7 Cells stained w/
PKH67
Used CTC 1st Section
1st Section 2nd section 2nd Section
1st Section 2nd Section
Percentage
Number Side Channel Main Channel Side Channel Main Channel Reservoir
Reservoir
HFRD3#322
15
33.33
13.33
53.33
0.00
0.00
0.00
(40% RBCs)
HFRD3#312
13
61.54
0.00
30.77
0.00
0.00
7.69
(40% RBCs)
HFRD3#315
16
43.75
0.00
18.75
0.00
6.25
0.00
(42% RBCs)

163

The recovery rate for 100 and 14.7 (mean number) cells at 750 µL/min with and without
target cells in the drain reservoir is shown in Figure 4.46. The captured rate with each
captured location with 750 µL/min is shown in Figure 4.47 and Figure 4.48 for 100 and 10
MCF-7 cells. The p-value (Probability associated with a Student's paired t-Test, with a twotailed distribution) between 100 and 10 MCF-7 cells was 0.39 without the cell trapped in the
drain reservoirs and 0.67 with cells trapped in the drain reservoirs. Figure 4.49 shows the
frequency of captured target cell based on the locations. The p-values (100 and 10 MCF-7
cells) for each location are also shown above the each pair of columns. The results show that
50 ± 8.4% (mean ± s.d.) of the target cells were captured in the first section (main and side
channel,) 30 ± 13.9% (mean ± s.d.) was captured in the second section (main and side
channel,) 7 ± 5.1% (mean ± s.d.) was trapped in the drain reservoirs, and 12 ± 13.8% (mean
± s.d.) were missed.
100
90

Recovery Rate (%)

80

85.67

84.94

89.58

76.00

70

100 CTCs

60
50

14.7 CTCs

40
30
20
10
0

CTCs w/o Reservoir

CTCs w/ Reservoir

Figure 4.46 Target cell capture (100 or 14.67 ± 1.53 (mean ± s.d.) MCF-7 cells in 40~42%
RBC at 750 µL/min) using HFRD3 with and without trapped cells in the drain reservoirs.
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P = 0.39
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8.33 ± 14.4%

34.28 ± 17.6%

Recovery Rate (%)

60

18.00 ± 9.6%
2nd section
Side Channel

50

4.44 ± 7.7%
9.33 ± 6.7%

40

1st Section
Main Channel
30

46.21 ± 14.3%
20

40.33 ± 14.6%
1st Section
Side Channel

10

0

100 CTCs

14.7 CTCs

Number of Spiked CTCs

Figure 4.47 Target cell capture (100 or 14.67 ± 1.53 (mean ± s.d.) MCF-7 cells in 40~42%
RBC at 750 µL/min) using HFRD3 for each location without trapped cells in the drain
reservoirs: Percentage of each location in the column indicates mean ± s.d. (Probability:
paired, two-tailed)
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2.08 ± 3.6%
4.44 ± 7.7%
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Figure 4.48 Target cell capture (100 or 14.67 ± 1.53 (mean ± s.d.) MCF-7 cells in 40~42%
RBC at 750 µL/min) using HFRD3 for each location with trapped cells in the drain reservoirs:
Percentage of each location in the column indicates mean ± s.d. (Probability: paired, twotailed)
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Figure 4.49 Frequency of captured target cells versus location for 100 and 14.67 ± 1.53
(mean ± s.d.) MCF-7 cell cases. The flow rate was 750 µL/min and RBC concentration was
40~42%. P-values between 100 and 14.67 ± 1.53 (mean ± s.d.) MCF-7 cell cases are above
the columns for each location. (Probability: paired, two-tailed)
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4.10

Conclusions

A high flow rate rare target cell capture device was successfully designed, fabricated, and
captured CTCs with a high recovery rate. Multiple processes including device design and
fabrication, surface functionalization, sample preparation, fluidic experiment, and target cell
identification were carefully performed. A new sealing method was introduced to solve a
sealing issue. New sample preparation method was established to overcome the limit of
dilution method and applied to rare target cell capture experiment. The average recovery rate
was 81% at 150 µL/min with 40 ~ 42 % RBCs from 100 viable MCF-7 cells. For 750 µL/min
cases, the average recovery rate was 76% from 100 viable MCF-7 cells and 85% from small
number of viable MCF-7 cells (13~16 cells.) Most of target cells (58% for 100 CTCs and 80%
for 14.67 ± 1.53 (mean ± s.d.) CTCs) were captured at the side channels. At high flow rates
(750 µL/min), exclusion of the target cells (< 14% for 100 CTCs and 10% for 14.67 ± 1.53
(mean ± s.d.) CTCs) was observed in the drain reservoirs. The target cell capture with whole
blood needs to be investigated and the optimum flow rate control at each outlet is required to
increase the recovery rate.
4.11
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CHAPTER 5: CONCLUSIONS AND FUTURE WORK

5.1 Conclusions
A new concept for a rare cell capture device at high flow rate was introduced to
overcome the limitations of current methods. Current devices have some combination of low
flow rate target cell capture, low recovery rate, low purity, or require pre-sample treatment.
The performance of the high flow rate device (HFRD) was evaluated using computational
fluid dynamics (CFD) simulations using Fluent v6.3 (ANSYS, Canonsburg, PA, USA). The
working fluid was water, a Newtonian fluid, and assumed that the target cells would follow
pathlines. These were used to identify the prospective device dimensions to optimize the
performance of the device. Based on the CFD simulation results, prototype HFRDs were
designed and fabricated in PMMA.
For precise sample preparation, a new protocol for isolating single or small numbers of
cells was introduced to solve the uncertainty inherent in the current method of preparing
spiked blood samples which is based on statistical methods. Single cells or exact number of
cells were successfully collected. The collected target cells were spiked in a red blood cell
solution. The concentration of RBCs was 40~42% to match the hematocrit of normal human
blood. Target cells were in a viable condition and stained with membrane fluorescence.
Additionally, the target cells, the MCF-7 cell line, were successfully cultured and preserved.
The HFRD prototypes were fabricated using hot embossing with micro milled brass mold
inserts. The HFRDs were UV modified to produce carboxyl groups on the surface and amine
functionalized. Antibodies were immobilized on the amine functionalized surface.
Monoclonal anti-EpCAM was used for high specific capture of target cells. Sealing of the
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HFRDs was completed using a spin coating technique. Since the aspect ratio of the HFRDs
was very low (less than 0.01) at the side channels and the hot embossed HFRD was not flat, a
new method was required instead of conventional thermoplastic fusion bonding. Thin PC
sheets were used as substrates and PMMA solution (mixed with PMMA beads and solvent)
was spin coated on the PC. The PMMA spin coated PC sheet could seal the HFRD. The
thermoplastic fusion bonding was not successful because it requires flat surfaces.
Circulating tumor cells, CTCs, were captured using antibody immobilized HFRD. The
flow rate was 750 µL/min and recovery rate was 80.47 ± 12.85% (sample mean ± sample
standard deviation) as a mean value of both cases for 100 and 14.67 ± 1.53 (sample mean ±
sample standard deviation) cells. The target cells were cultured MCF-7 cells and 100 or a
small numbers of viable cells (13~16 cells) were used.
5.1.1

Simulation of High Flow Rate Devices

The goal of the design and the simulation was to find optimized dimensions to realize
high flow rate (750 µL/min) with maximum target cell recovery in a micro device with a
small footprint.

Although the high flow rate device was designed and fabricated based on

the simulation results, the simulation conditions were not those of the actual fluid, which was
non-Newtonian with millions of solid blood cells in solution. Therefore, further simulations
may give better performance.
A new concept of the high flow rate cell capture design was verified by CFD simulation.
The velocity vector was manipulated by adding side channels on the main channel. The
lateral velocity vector was created and the pathlines or stream lines directed toward the side
channel. The mean axial velocity was minimized to maximize the recovery rate. The lateral
velocity along the contact path, the velocity at the point of target cell collision with the side
172

channel, was investigated to avoid target cell loss through the side channel. To optimize the
HFRD design, 20 cases were simulated. Based on the simulation results, multiple designs
were chosen and fabricated to test the performance. From the results, the original design was
modified and simulated again. The final design was HFRD3. The first section has 40 mm
long, 5~10 mm wide, and 130~30 µm deep main channel with 5 µm deep side channels. The
second section has 33 mm long, 10 mm wide, and 30 µm deep main channel with 5 µm deep
side channels. The end of second section was connected with drain reservoir without side
channels to avoid clogging by leukocytes.
The inlet velocity was reduced to minimize the maximum velocities (axial and lateral
velocities) by increasing the inlet cross-sectional area. The variable depth region of the main
channel was designed to decrease the depth of the main channel to increase the encounter
rate in the second section of the main channel. The length of the variable depth region was 40
times larger than initial depth of the variable depth region of the main channel to avoid
sudden velocity increase in that area. Since the depth of the side channel is 5 µm, red blood
cells could be filtered out through side channels, while the target cells should not pass
through.
5.1.2

Rare Sample Preparation for CTC Capture

Sample preparation has been an issue in CTC studies because methods of preparation of a
single or precise number of CTCs in suspension has not been reported or was not suitable for
CTC capture using a micro device. Therefore, a new protocol for collection of a single or
precise number of cells was established. MCF-7 cells were successfully collected using a
capillary tube with the polyimide removed and a cell collection chip. The target cells
collected in the capillary were transported to the desired location, and spiked in blood.
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5.1.3

Fabrication of a High Flow Rate Device

A high flow rate device was designed and fabricated based on the simulation results.
Mold insert fabrication was completed using micro milling. The mold insert was successfully
hot embossed in polymethyl methacrylate (PMMA.) The PMMA high flow rate device was
UV modified for carboxyl group and amine functionalization and antibody immobilization
process were followed. The HFRD3 was sealed using a spin coating technique. To achieve
very low aspect ratio sealing, a new protocol of spin coating sealing method was established.
5.1.4

Target Cell Capture Using High Floe Rate Device Three

A statistically-prepared target cell sample, normally 100 MCF-7 cells, and an exact
number of target cells, 14~16 MCF-7 cells using the new cell collection method, were used
to capture the target cells using the final prototype. The target cells could be captured using
the antibody immobilized surface in the device. A flow rate of 750 µL/min and mixture with
~ 40% human red blood cells used. The recovery rate was 76 ± 6.56% (sample mean ±
sample standard deviation) from the cell sample 100 and 84.94 ± 19.81% (sample mean ±
sample standard deviation) from the small number of CTCs, 14.67 ± 1.53% (sample mean ±
sample standard deviation) and confidence level with 95% = 1.73.
5.2 Future Work
The high flow rate target cell capture from human whole blood is a necessary step for
further clinical applications in particular, point-of-care. The effect of leukocytes needs to be
tested and may be minimized by modification of the plain cover sheet. Clinical tests with
patient`s blood is the next step for the clinical use.
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The recovery rate will be increased by manipulating the flow rate at each outlet and
modification of the main outlet area. Moreover, a nano- or submicro-patterned cover sheet
may increase the recovery rate and purity of the captured target cells. The footprint can be
reduced by eliminating unnecessary area. Thermoplastic fusion bonding will be applied for
HFRD sealing to expand the capture surface.
To capture EpCAM negative CTCs, multiple antibodies can be immobilized on the
capture zone. The prototype can also be used for detection of infection disease by inverting
the function and placing capture zone in the side channel. Methicillin-resistant
Staphylococcus aureus (MRSA) or Escherichia coli (E. Coli) can be captured with proper
antibodies in the side channels.
The HFRD3 can be used for a smart blood cell collection tube. The HFRD3 can be
embedded in the tube and capture the target cells or viruses. The HFRD3 can be a portable
capture device for cancer or infection disease. The HFRD3 can be combined with PCR or
LDR micro device using a modular concept to eliminate false-positive results.
Simulation of CTC collision/exclusion at the side channel can give very variable and
critical information for the next generation of the HFRDs. The exclusion conditions (side
channel depth, pressure gradient, and binding force) may give selective exclusion with proper
channel dimensions and operating conditions.
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APPENDIX A: CUSTOM MADE PLUNGER SPRING ASSISTED JIG AND
LOCAL PRESSURE CONTROL METHOD
A custom made plunger spring assisted jig (designed and fabricated by Dr. Daniel
Sangwon Park in Louisiana State University) was used for thermoplastic fusion bonding. The
jig was used to manipulate local pressure at each point of plunger. However, the pressure
variation over the whole device may not be much different since the pressure of each plunger
spring amy dispersed due to the thick glass on the outside of the high flow rate device. Figure
A.1 and Figure A.2 show the jig and assembled condition with the device and the glasses.

Plunger spring
Figure A.1 Custom made plunger spring assisted jig for thermoplastic fusion bonding

Glasses

High flow rate device with cover sheet
Figure A.2 Custom made plunger spring assisted jig assembled with high flow rate device
and glasses
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Local pressure control sheets were used to avoid channel deformation on the main and
side channel. A Kapton tape (MSK00052, 1stmaskingtape, Torrance, CA, USA) was put on
the high flow rate device and removed the channel area only. The channel area removed
Kapton tape can control the local pressure. The substrate was the high flow rate device which
has symmetric geometry. The local pressure control sheet was assembled with the high flow
rate device and an alignment guide to give the pressure on only the Kapton tape area during
thermoplastic fusion bonding process. Figure A3. And Figure A.4 show the local pressure
control sheets, high flow rate device with Kapton tape, with and without alignment guide.

Symmetric of high flow rate device

Channel area removed kapton tape

Figure A.3 Local pressure control sheet
Kapton tape removed channel area
Guide for alignment

Channel area removed kapton tape

Figure A.4 Local pressure control sheet with alignment guide
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APPENDIX B: WATER CONTACT ANGLE DATA
The water contact angle of hot embossed PMMA was measured to assess the effects of
UV modification and IPA rinsing. Hot embossed PMMA showed 92° a water contact angle
without UV treatment and it became more hydrophobic after UV modification. After an IPA
rinse the UV modified PMMA water contact angle was decreased by about 20°. Figure B.1
shows the water contact angle changes after UV modification and after the IPS rinse. Each
value was an average number of left and right water contact angle, and it rearranged from the
low to high in each column.

Table B.1 Water contact angle of hot embossed PMMA before and after IPA rinse.

Measurements

Exposure 0 minutes
None UV
Steps
time
87.50
90.00
90.50
90.50
91.50
92.00
92.50
92.50
93.50
93.50
93.50
94.00
94.50

Average

92.00

5 minutes
10 minutes
15 minutes
After After After After After After
81.50 69.50 83.50 60.50 86.00 71.50
UV Rinse
UV
Rinse
UV
Rinse
84.00
74.00 92.50
61.00 91.00
71.50
86.50 74.50 93.00 63.50 95.50 72.00
87.00 74.50 95.50 67.00 98.00 72.50
88.00 74.50 97.00 69.00 98.50 74.00
89.00
97.50 70.00 99.50 74.00
89.00
98.00 70.50 99.50 74.50
89.00
99.00 73.00 99.50 74.50
89.00
100.5 73.50 100.00 75.00
89.50
101.00 74.00 100.50 75.00
90.00
101.50 74.00 100.50 75.00
91.00
75.00 101.00 75.50
93.00
78.00 101.00
96.00
79.50 102.00
97.00
102.00
97.50
102.50
89.81 73.40 96.27 70.61 98.56 73.75
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Table B.1 Water contact angle of hot embossed PMMA before and after IPA rinse (continued)

Measurements

Exposure time
20 minutes
30 minutes
After UV After Rinse After UV After Rinse
Steps
90.50
68.00
77.50
67.00
91.50
68.50
78.50
69.00
91.50
69.00
78.50
69.00
91.50
69.50
79.50
70.50
93.50
71.00
80.00
71.50
93.50
71.00
81.00
72.00
94.00
71.50
81.50
72.50
94.00
71.50
83.50
73.00
94.50
72.50
84.50
73.50
95.00
72.50
85.50
75.00
95.50
86.50
75.50
96.50
86.50
79.00
96.50
86.50
79.00
99.00
82.00
99.00
101.50
Average
94.84
70.50
82.27
73.46
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60 minutes
After Rinse
73.50
76.00
76.00
77.00
77.00
77.00
78.50
79.50
79.50
79.50
81.00
83.50
84.50
85.50
88.00
79.73

APPENDIX C: CELL CULTURE, PRESERVATION, AND THAWING

C.1 MCF-7 Cell Line Culture Process
The MCF-7 cell line was cultured for the cell capture experiments. The complete growth
medium for the MCF-7 cell line was a mixture of high glucose Dulbecco's Modified Eagle
Medium (DMEM) from GIBCO (Carlsbad, California, USA) or Eagle's Minimum Essential
Medium (EMEM) from ATCC (Manassas, VA, USA.) Heat-Inactivated Fetal Bovine Serum
(FBS) from GIBCO (Carlsbad, California, USA), Penicillin-Streptomycin Solution (P/S)
from ATCC (Manassas, VA, USA), and an insulin solution from bovine pancreas (B/I) from
INVITROGEN (Carlsbad, California, USA.) The cell line was cultured in T-25 tissue culture
flasks from BD Biosciences (Franklin Lakes, NJ, USA.) The basic cell culture products and
companies are shown in the Table C.1. The conditions for the cell culture were 95% air and 5%
carbon dioxide at 37 °C. The media were changed every 2 ~ 3 days and the MCF-7 cells
were subcultured before they fully occupied the T-25 flask surface. The mixing ratio of the
each solution was DMEM 450 ml, FBS 50 ml, P/S 5 ml, and B/I 500 μl. Figure C.1 shows
the cultured MCF-7 cells in a T25 flask. The protocol for making the growth medium is
explained in Table C.2.
Table C.1 Cell culture products and companies
Product
Dulbecco's Modified Eagle Medium
Eagle's Minimum Essential Medium
Heat-Inactivated Fetal Bovine Serum
Penicillin-Streptomycin Solution
Insulin solution from bovine pancreas
T-25 tissue culture flasks

Company
GIBCO (Carlsbad, California, USA)
ATCC (Manassas, VA, USA)
GIBCO (Carlsbad, California, USA)
ATCC (Manassas, VA, USA)
INVITROGEN (Carlsbad, California, USA)
BD Biosciences (Franklin Lakes, NJ, USA)
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(a)

(b)

Figure C.1 Culturing MCF-7 cells (p-159) (a) for one day and (b) for five days from
subculture

Table C.2 Protocol for making complete growth medium for MCF-7 cell line
Step
1
2
3
4
5
6

Process
DMEM 450 ml (Remove 50 ml of DMEM from 500 ml bottle)
Add 10% FBS (50 ml FBS)
Add 100U P/S (5 ml Penicillin - Streptomycin)
Add 0.01 mg/ml B/I (500 μl Bovine Insulin)
Mix the solution well and aliquot the medium in 50 ml tubes
Store the 50 ml tubes in 4 °C

The first rule of the cell culture is to avoid contamination which changes the properties or
morphology of the cells and eventually can kill the cells. Recovering and finding the
contamination source should be carefully performed by sterilizing all cell culture supplies,
including all surfaces of the bio safety cabinet and incubator using 70% ethyl alcohol.
Pipettes and pipette tips need to be autoclaved. Moreover, the cell culture medium needs to
be checked. Incubation of only the medium can confirm the presence contamination using a
microscope. Figure C.2 shows the contaminated MCF-7 cells and contaminated medium.
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(a)

(b)

Figure C.2 Contamination of the cells: (a) contaminated MCF-7 cells after 3 day
subculture and (b) contaminated medium after 3 day incubation

Subculture of the MCF-7 cell was done when the MCF-7 cells occupied 80 ~ 90% of the
area in the T25 flask. Subculturing or passaging the attached cells required trypsinization.
The trypsinization time was minimized to obtain healthy cells and to maximize cell viability.
The protocol for the MCF-7 cell line subculture is shown in Table C.3.
Table C.3 Protocol of MCF-7 cell line subculture
Step
1
2
3
4
5
6

Process
Discard media and add PBS (3 ml) in a T25 flask for washing
Discard the PBS and put 1 ml trypsin in the T25 flask
Incubate in CO2 incubator about 10 min
(Do
not rock
or pre-warmed
shake the flask media
to avoidin
cell
Prepare
4 ml
a clumping)
new T25 flasks
Confirm the cell detachment using a invert microscope
Add 3 ml media in the flask and then transfer to 10 ml centrifuge

7
8
9
10

Centrifuge
at 125 x g for 5 ~ 10 min at 20 °C
tube
Discard the supernatant solution (media and trypsin) and remain cell
Add 1ml media and carefully pipette several times
pellet
Put the cell suspension in the new flasks containing 4ml media

182

C.2 Cell Preservation and Thawing
Preservation of the cultured cells was done using dry ice instead of an ultra low
temperature deep freezer since the temperature of the dry ice is -78.5°C. The freezing media
were 50% cell culture media, 40% FBS, and 10% Dimethylsulfoxide (DMSO, from ATCC,
Manassas, VA, USA.) Alternatively, 90% FBS and 10% DMSO was also used as cell
freezing media. The cell stock solution, cultured cells in cell freezing media, was transferred
in 2 mL cryovial and then inserted in an IPA filled cell freezing container (Mr. Frosty from
Sigma, St. Louis, MO, USA.) The cell freezing container was placed in an insulation box and
fully filled with dry ice. The rate of temperature decrease in the IPA-filled cell freezing
container was approximately -1°C /min which is the optimum condition for freezing common
cells. The cell freezing process should be done quickly to maximize the cell viability because
the Dimethylsulfoxide (DMSO) can damage the cells. The cells should be healthy and the
cell culture media should be changed one day before cell freezing. During cell should be
taken of contamination. Cell freezing using dry ice is shown in Figure 4.16. The temperature
of the cells in dry ice was around -74°C. After 8 ~ 12 hours, the frozen cell stock in dry ice
was stored in a liquid nitrogen tank. The cell stock information (cell type, passage number,
cell freezing media, date, stock volume, and canister and cane number in liquid nitrogen tank)
was well recorded.
The frozen cell or cell stock was thawed to culture. Thawing the cells should be done as
quickly as possible to minimize the cell damage from DMSO. Table C.4 shows the protocol
for cell thawing.
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(a)

(b)

Figure C.3 Cell freezing using dry ice: (a) cryovial in the cell freezing container and (b)
insulation box with cell freezing container and dry ice

Table C.4 Protocol of Cell Thawing
Step

Process

1

Place the 50 ml cell growth medium in a 37 °C water bath over 30 minute.

2

Prepare 10 ml media in a 15ml centrifuge tube and 4 ml media in a T25 flask.

3

Put a frozen cell stock into a 37 °C water bath for 1-2 minutes until it thawed.
(Do not to totally immerse the stock sample - this may cause contamination)

4

Transfer the cell stock into the centrifuge tube containing 10 ml media.

5

Centrifuge at 125 x g (1000 rpm for 10 ml tube) for 5 min at 20 °C.

6

Discard supernatant media and add 1 ml media in the tube.

7

Slowly pipette the whole cell stock.

8

Transfer the cell solution into the flask containing pre-warmed medium (4 ml for T25).

9

Incubate in a CO2 incubator

10

Change media on next day
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APPENDIX D: TARGET CELL CAPTURE DATA

Captured target cells in the high flow rate device3 (HFRD3) were counted at each
location. Table D.1 shows the location of captured target cells. The prospective number of
target cells (MCF-7) was 100 which were prepared using dilution method. The flow rate was
750 µL/min and concentration of the RBC was 40~42% for all cases.

Table D.1 Location of captured MCF-7 cells from100 cells
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), 100 Live MCF-7 Cells stained w/ PKH67

100 CTCs

Collected
CTCs

1st Section
Side
Channel

1st Section
Main
Channel

2nd section
Side
Channel

2nd Section
Main
Channel

1st Section
Reservoir

2nd Section
Reservoir

HFRD3#310
(42% RBCs)

100

52

2

29

0

16

0

HFRD3#306
(40% RBCs)

100

24

15

11

25

6

0

HFRD3#303
(40% RBCs)

100

45

11

14

0

7

0
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Table D.2 shows the location of captured target cells from small number of the MCF-7
cells. Exact number of MCF-7 cells was spiked in RBC solution using cell collection chip
and polyimide removed capillary. The flow rate was 750 µL/min and the concentration of the
RBCs was 40~42% for all cases.

Table D.2 Number of captured target cells for each location in the high flow rate device3
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of Live MCF-7 Cells stained w/
PKH67
Small # of
CTCs

CTC
Number

1st Section
Side
Channel

1st Section
Main
Channel

2nd section
Side
Channel

2nd Section
Main
Channel

1st Section
Reservoir

2nd Section
Reservoir

HFRD3#322
(40% RBCs)

15

5

2

8

0

0

0

HFRD3#312
(40% RBCs)

13

8

0

4

0

0

1

HFRD3#315
(42% RBCs)

16

7

0

3

0

1

0

Table D.3 Percentage of captured target cells for each location (Converted from Table D.2 )
Q=750 µL/min (Wr=Wl=200 µL/min, Wo=350 µL/min), small number of Live MCF-7 Cells stained w/
PKH67
Percentage

CTC
Number

1st Section
1st Section 2nd section 2nd Section
Side Channel Main Channel Side Channel Main Channel

1st Section
Reservoir

2nd Section
Reservoir

HFRD3#322
(40% RBCs)

15

33.33

13.33

53.33

0.00

0.00

0.00

HFRD3#312
(40% RBCs)

13

61.54

0.00

30.77

0.00

0.00

7.69

HFRD3#315
(42% RBCs)

16

43.75

0.00

18.75

0.00

6.25

0.00
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Double cells

Double cells

Figure D.1 Captured MCF-7 cells from HFRD3#322: 15 of 15 cells in the channels
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Trapped cell in
the drain reservoir

Figure D.2 Capture MCF-7 cells from HFRD3#312: 12 of 13 cell in the channel and 1 cells
in the drain reservoir
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Trapped cell in the
drain reservoir

Double cells

Figure D.3 Capture MCF-7 cells from HFRD3#315: 10 of 16 cells in the channel and 1 cell
in the drain reservoir
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APPENDIX E: PROTOCOL FOR THERMOPLASTIC FUSION BONDING
1. Preparation of the thermal bonding (flatting, dehydration, and cleaning)
a. Check the flatness of the polymer device
Light reflection on the device surface may a good simple way to check the flatness.
b. Put the polymer device, cover slip, and glasses in 80°C oven for overnight for
dehydration and annealing
If the device was bended, use paper clips to press a sandwich assembled chip with two
thick glasses (over 1 cm).
c. Blow out any dust or particle on the device using nitrogen gas
Blow at low pressure with over 10 cm distance from the device to avoid any liquid drop
formation.
2. Appling pressure and temperature for thermal bonding
a. Assemble the polymer device with cover slip between thin pieces of glass
Use gloves always, do not touch the bonding surface.
b. Put the assembled polymer device, cover slip, and glasses in a 50°C pre-set oven
c. Put a weight on top of the glass
The pressure needs to be calculate based on the contact area and the weight
d. Set the operating temperature at the desired point
The operating temperature needs to be control based on the materials and the thermal
bonding results.
Recommending operating temperatures are 105°C for pristine PMMA, 101°C for UV
modified PMMA, and 150°C for pristine PC.
 The operating temperature and pressure need to be control as a combination.
 The temperature increasing rate should be control not to be over the target
temperature.
e. Wait for two hours and set the temperature at 50°C
f. Wait over 30 minutes until the temperature cools down to around 60°C and take
away the thermal bonded device from the oven
g. Separate the sandwich assembled device from the glasses
The glass will be pot up from the polymer device if the warmed sandwich assembled
glasses and device put on a cold metal surface
3. Testing
 Sealing test can be done by pushing air using syringe in water after capillary
connection process
To visualize the sealing performance, food color or fluorescence may be useful.
 Deformation test can be done by looking the cross section of the channel under
microscope
Sandpaper and polymer polishing chemicals may help to clean the cross section
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APPENDIX F: PROTOCOL OF AMINE FUNCTIONALIZATION
1. Preparation of the amine functionalization solution
Mix smoothly 0.659 g EDC + 1 ml Ethylenediamine + 100 ml PBS
(Modified dilution: 3.25 g EDC + 5 ml Ethylenediamine + 500 ml PBS)
2. Draw the amine functionalization solution into the channel by withdrawing
3. Wait until the solution filled all the channel
4. Shake the solution fully filled PMMA device for 60 minutes
5. Do the step 2 ~4 again to confirm the amine functionalization
6. Dry by nitrogen gas
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